NAOTO T UENO

TitleProfessor
InstitutionMD Anderson
DepartmentBreast Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ha SYY, Anami Y, Yamazaki CM, Xiong W, Haase CM, Olson SD, Lee J, Ueno NT, Zhang N, An Z, Tsuchikama K. An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates. Mol Cancer Ther. 2022 09 06; 21(9):1449-1461. PMID: 35793453.
      Citations:    Fields:    
    2. Farley CR, Irwin S, Adesoye T, Sun SX, DeSnyder SM, Lucci A, Shaitelman SF, Chang EI, Ueno NT, Woodward WA, Teshome M. Lymphedema in Inflammatory Breast Cancer Patients Following Trimodal Treatment. Ann Surg Oncol. 2022 Oct; 29(10):6370-6378. PMID: 35854031.
      Citations: 1     Fields:    
    3. Cobb AN, Diao K, Teshome M, Lucci A, Ueno NT, Stauder M, Layman RM, Kuerer HM, Woodward WA, Sun SX. Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. Ann Surg Oncol. 2022 Oct; 29(10):6381-6392. PMID: 35834145.
      Citations:    Fields:    
    4. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res. 2022 07 01; 28(13):2878-2889. PMID: 35507014.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    5. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022 07 07; 387(1):9-20. PMID: 35665782.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    6. Xie X, Lee J, Iwase T, Kai M, Ueno NT. Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape. Expert Opin Ther Targets. 2022 05; 26(5):405-425. PMID: 35574694.
      Citations: 1     Fields:    Translation:HumansAnimals
    7. Su F, Wang X, Pearson T, Lee J, Krishnamurthy S, Ueno NT, Kolonin MG. Erratum: Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis. Mol Ther Oncolytics. 2022 Jun 16; 25:305-306. PMID: 35663226.
      Citations:    
    8. Villodre ES, Hu X, Eckhardt BL, Larson R, Huo L, Yoon EC, Gong Y, Song J, Liu S, Ueno NT, Krishnamurthy S, Pusch S, Tripathy D, Woodward WA, Debeb BG. NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. J Natl Cancer Inst. 2022 04 11; 114(4):579-591. PMID: 34893874.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    9. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5). PMID: 35267631.
      Citations:    
    10. Masuda H, Harano K, Miura S, Wang Y, Hirota Y, Harada O, Jolly MK, Matsunaga Y, Lim B, Wood AL, Parinyanitikul N, Jin Lee H, Gong G, George JT, Levine H, Lee J, Wang X, Lucci A, Rao A, Schweitzer BL, Lawrence OR, Seitz RS, Morris SW, Hout DR, Nakamura S, Krishnamurthy S, Ueno NT. Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precis Oncol. 2022 03; 6:e2000368. PMID: 35294223.
      Citations:    Fields:    Translation:HumansCells
    11. Fong LWR, Lee J, Lin HK, Ueno NT, Zhang S. A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer. Sci Rep. 2022 02 15; 12(1):2478. PMID: 35169199.
      Citations:    Fields:    Translation:HumansCells
    12. Rypens C, Bertucci F, Finetti P, Robertson F, Fernandez SV, Ueno N, Woodward WA, Van Golen K, Vermeulen P, Dirix L, Viens P, Birnbaum D, Devi GR, Cristofanilli M, Van Laere S. Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. NPJ Breast Cancer. 2022 Jan 18; 8(1):12. PMID: 35042871.
      Citations: 2     
    13. Semba T, Wang X, Xie X, Cohen EN, Reuben JM, Dalby KN, Long JP, Phi LTH, Tripathy D, Ueno NT. Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated With an Immunosuppressive Tumor Microenvironment. J Natl Cancer Inst. 2022 01 11; 114(1):97-108. PMID: 34250544.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    14. Ueno NT, Alexander A. "Why and What" for the optimal management of inflammatory breast cancer. Chin Clin Oncol. 2021 Dec; 10(6):54. PMID: 34930010.
      Citations:    Fields:    Translation:Humans
    15. Nakano H, Miyamoto T, Janjigian YY, Mine S, Mitsuya H, Ueno NT, Sharon E, Sakai S, Timmer WC, Nakabo S, Ikeuchi T, Fujiwara S, Kinjo M, Inuzuka T, Kume H, Shirai K, Yamaguchi N, Takabe K, Takebe N. Advances in Oncology in US and Japan: Focusing on Cancer and Infectious Diseases. World J Oncol. 2021 Dec; 12(6):183-194. PMID: 35059078.
      Citations:    
    16. Kai M, Marx AN, Liu DD, Shen Y, Gao H, Reuben JM, Whitman G, Krishnamurthy S, Ross MI, Litton JK, Lim B, Ibrahim N, Kogawa T, Ueno NT. A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. Sci Rep. 2021 11 15; 11(1):22242. PMID: 34782633.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    17. Lim B, Peterson CB, Davis A, Cho E, Pearson T, Liu H, Hwang M, Ueno NT, Lee J. ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells. Biomedicines. 2021 Oct 07; 9(10). PMID: 34680527.
      Citations:    
    18. Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2021 10 01; 27(19):5365-5375. PMID: 34253579.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    19. Iwase T, Blenman KRM, Li X, Reisenbichler E, Seitz R, Hout D, Nielsen TJ, Schweitzer BL, Bailey DB, Shen Y, Zhang X, Pusztai L, Ueno NT. A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers (Basel). 2021 Sep 28; 13(19). PMID: 34638323.
      Citations: 2     
    20. Villodre ES, Hu X, Larson R, Finetti P, Gomez K, Balema W, Stecklein SR, Santiago-Sanchez G, Krishnamurthy S, Song J, Su X, Ueno NT, Tripathy D, Van Laere S, Bertucci F, Vivas-Mejía P, Woodward WA, Debeb BG. Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. Mol Oncol. 2021 10; 15(10):2752-2765. PMID: 34342930.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    21. Balema W, Liu D, Shen Y, El-Zein R, Debeb BG, Kai M, Overmoyer B, Miller KD, Le-Petross HT, Ueno NT, Woodward WA. Inflammatory breast cancer appearance at presentation is associated with overall survival. Cancer Med. 2021 09; 10(18):6261-6272. PMID: 34327874.
      Citations: 1     Fields:    Translation:Humans
    22. Adesoye T, Babayemi O, Postlewait LM, DeSnyder SM, Sun SX, Woodward WA, Ueno NT, Hunt KK, Lucci A, Teshome M. Inflammatory Breast Cancer at the Extremes of Age. Ann Surg Oncol. 2021 Oct; 28(10):5626-5634. PMID: 34292426.
      Citations: 2     Fields:    Translation:Humans
    23. Park J, Tacam MJ, Chauhan G, Cohen EN, Gagliardi M, Iles LR, Ueno NT, Battula VL, Sohn YK, Wang X, Kim HS, Krishnamurthy S, Fowlkes NW, Green MM, Bartholomeusz GA, Tripathy D, Reuben JM, Bartholomeusz C. Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression. Breast Cancer Res Treat. 2021 Sep; 189(2):333-345. PMID: 34241740.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    24. Lee J, Liu H, Pearson T, Iwase T, Fuson J, Lalani AS, Eli LD, Diala I, Tripathy D, Lim B, Ueno NT. PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening. Biomedicines. 2021 Jun 28; 9(7). PMID: 34203351.
      Citations: 2     
    25. McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin SY. Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al. Ann Oncol. 2021 09; 32(9):1194-1197. PMID: 34166757.
      Citations: 1     Fields:    Translation:Humans
    26. Fujii T, Masuda H, Cheng YC, Yang F, Sahin AA, Naoi Y, Matsunaga Y, Raghavendra A, Sinha AK, Fernandez JRE, James A, Yamagishi K, Matsushima T, Schuetz R, Tripathy D, Tada S, Jackson RS, Noguchi S, Nakamura S, Acoba JD, Ueno NT. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Res Treat. 2021 Sep; 189(2):455-461. PMID: 34131830.
      Citations: 2     Fields:    Translation:Humans
    27. Postlewait LM, Teshome M, Adesoye T, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, Sun SX, Woodward WA, Le-Petross HT, Valero V, Ueno NT, Lucci A. Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Dec; 28(13):8610-8621. PMID: 34125346.
      Citations: 1     Fields:    Translation:Humans
    28. Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, Ueno NT, Zhang N, An Z, Tsuchikama K. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021 06 10; 12(1):3528. PMID: 34112795.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    29. Chainitikun S, Espinosa Fernandez JR, Long JP, Iwase T, Kida K, Wang X, Saleem S, Lim B, Valero V, Ueno NT. Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. PLoS One. 2021; 16(4):e0250057. PMID: 33861773.
      Citations: 1     Fields:    Translation:Humans
    30. McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, Lin SY. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021 05; 32(5):661-672. PMID: 33736924.
      Citations: 121     Fields:    Translation:Humans
    31. Iwase T, Parikh A, Dibaj SS, Shen Y, Shrimanker TV, Chainitikun S, Kida K, Sapon ME, Sahin O, James A, Medrano AYD, Klopp AH, Ueno NT. The Prognostic Impact of Body Composition for Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy. Cancers (Basel). 2021 Feb 04; 13(4). PMID: 33557032.
      Citations:    
    32. Kida K, Olver I, Yennu S, Tripathy D, Ueno NT. Optimal Supportive Care for Patients With Metastatic Breast Cancer According to Their Disease Progression Phase. JCO Oncol Pract. 2021 04; 17(4):177-183. PMID: 33492987.
      Citations:    Fields:    Translation:Humans
    33. Iwase T, Wang X, Shrimanker TV, Kolonin MG, Ueno NT. Body composition and breast cancer risk and treatment: mechanisms and impact. Breast Cancer Res Treat. 2021 Apr; 186(2):273-283. PMID: 33475878.
      Citations: 6     Fields:    Translation:Humans
    34. Hu X, Villodre ES, Larson R, Rahal OM, Wang X, Gong Y, Song J, Krishnamurthy S, Ueno NT, Tripathy D, Woodward WA, Debeb BG. Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer. Commun Biol. 2021 01 15; 4(1):72. PMID: 33452400.
      Citations: 11     Translation:HumansCells
    35. Yamaguchi A, Anami Y, Ha SYY, Roeder TJ, Xiong W, Lee J, Ueno NT, Zhang N, An Z, Tsuchikama K. Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope. Bioorg Med Chem. 2021 02 15; 32:116013. PMID: 33482584.
      Citations: 1     Fields:    Translation:HumansCells
    36. Partain N, Postlewait LM, Teshome M, Rosso K, Hall C, Song J, Meas S, DeSnyder SM, Lim B, Valero V, Woodward W, Ueno NT, Kuerer H, Lucci A. The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Aug; 28(8):4265-4274. PMID: 33403525.
      Citations: 4     Fields:    Translation:Humans
    37. Xie X, Lee J, Liu H, Pearson T, Lu AY, Tripathy D, Devi GR, Bartholomeusz C, Ueno NT. Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis. Mol Cancer Ther. 2021 02; 20(2):296-306. PMID: 33323457.
      Citations: 3     Fields:    Translation:HumansAnimals
    38. Villodre ES, Gong Y, Hu X, Huo L, Yoon EC, Ueno NT, Woodward WA, Tripathy D, Song J, Debeb BG. NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer. Cancers (Basel). 2020 Dec 10; 12(12). PMID: 33321961.
      Citations: 5     
    39. Kida K, Hess KR, Lim B, Iwase T, Chainitikun S, Valero V, Lucci A, Le-Petross HC, Woodward WA, Krishnamurthy S, Hortobagyi GN, Tripathy D, Ueno NT. Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers (Basel). 2020 Oct 24; 12(11). PMID: 33114311.
      Citations:    
    40. Wang X, Semba T, Phi LTH, Chainitikun S, Iwase T, Lim B, Ueno NT. Targeting Signaling Pathways in Inflammatory Breast Cancer. Cancers (Basel). 2020 Sep 01; 12(9). PMID: 32883032.
      Citations: 6     
    41. Nilanon T, Nocera LP, Martin AS, Kolatkar A, May M, Hasnain Z, Ueno NT, Yennu S, Alexander A, Mejia AE, Boles RW, Li M, Lee JSH, Hanlon SE, Cozzens Philips FA, Quinn DI, Newton PK, Broderick J, Shahabi C, Kuhn P, Nieva JJ. Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters. JCO Clin Cancer Inform. 2020 09; 4:839-853. PMID: 32970482.
      Citations: 3     Fields:    Translation:Humans
    42. Costelloe CM, Lin PP, Chuang HH, Amini B, Chainitikun S, Yu TK, Ueno NT, Murphy WA, Madewell JE. Bone Metastases: Mechanisms of the Metastatic Process, Imaging and Therapy. Semin Ultrasound CT MR. 2021 Apr; 42(2):164-183. PMID: 33814103.
      Citations:    Fields:    Translation:Humans
    43. Chainitikun S, Saleem S, Lim B, Valero V, Ueno NT. Update on systemic treatment for newly diagnosed inflammatory breast cancer. J Adv Res. 2021 03; 29:1-12. PMID: 33842000.
      Citations:    Fields:    Translation:Humans
    44. Su F, Wang X, Pearson T, Lee J, Krishnamurthy S, Ueno NT, Kolonin MG. Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis. Mol Ther Oncolytics. 2020 Sep 25; 18:579-586. PMID: 32995482.
      Citations: 4     
    45. Chainitikun S, Long JP, Rodriguez-Bautista R, Iwase T, Tripathy D, Fujii T, Ueno NT. The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. Breast Cancer Res Treat. 2020 Oct; 183(3):729-739. PMID: 32720114.
      Citations: 1     Fields:    Translation:Humans
    46. Postlewait LM, Teshome M, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, Woodward WA, Ueno NT, Lucci A. Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery? Ann Surg Oncol. 2020 Nov; 27(12):4603-4612. PMID: 32710271.
      Citations: 6     Fields:    Translation:Humans
    47. Gagliardi M, Pitner MK, Park J, Xie X, Saso H, Larson RA, Sammons RM, Chen H, Wei C, Masuda H, Chauhan G, Kondo K, Tripathy D, Ueno NT, Dalby KN, Debeb BG, Bartholomeusz C. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. Sci Rep. 2020 05 22; 10(1):8537. PMID: 32444778.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    48. Iwase T, Harano K, Masuda H, Kida K, Hess KR, Wang Y, Dirix L, Van Laere SJ, Lucci A, Krishnamurthy S, Woodward WA, Layman RM, Bertucci F, Ueno NT. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer. 2020 May 18; 20(1):430. PMID: 32423453.
      Citations: 2     Fields:    Translation:Humans
    49. Espinosa Fernandez JR, Eckhardt BL, Lee J, Lim B, Pearson T, Seitz RS, Hout DR, Schweitzer BL, Nielsen TJ, Lawrence OR, Wang Y, Rao A, Ueno NT. Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research. PLoS One. 2020; 15(4):e0231953. PMID: 32353087.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    50. Semba T, Sammons R, Wang X, Xie X, Dalby KN, Ueno NT. JNK Signaling in Stem Cell Self-Renewal and Differentiation. Int J Mol Sci. 2020 Apr 09; 21(7). PMID: 32283767.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    51. Chun YS, Mizuno T, Cloyd JM, Ha MJ, Omichi K, Tzeng CD, Aloia TA, Ueno NT, Kuerer HM, Barcenas CH, Vauthey JN. Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. Eur J Surg Oncol. 2020 09; 46(9):1588-1595. PMID: 32253074.
      Citations: 7     Fields:    Translation:Humans
    52. Le Du F, Fujii T, Kida K, Davis DW, Park M, Liu DD, Wu W, Chavez-MacGregor M, Barcenas CH, Valero V, Tripathy D, Reuben JM, Ueno NT. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy. PLoS One. 2020; 15(3):e0229903. PMID: 32214335.
      Citations: 13     Fields:    Translation:HumansCells
    53. Dilruba S, Grondana A, Schiedel AC, Ueno NT, Bartholomeusz C, Cinatl J, McLaughlin KM, Wass MN, Michaelis M, Kalayda GV. Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin. Cells. 2020 02 24; 9(2). PMID: 32102425.
      Citations: 5     Fields:    Translation:HumansCells
    54. Rypens C, Marsan M, Van Berckelaer C, Billiet C, Melis K, Lopez SP, van Dam P, Devi GR, Finetti P, Ueno NT, Bertucci F, Dirix P, Neven P, Vermeulen P, Dirix L, Van Laere SJ. Inflammatory breast cancer cells are characterized by abrogated TGFß1-dependent cell motility and SMAD3 activity. Breast Cancer Res Treat. 2020 Apr; 180(2):385-395. PMID: 32043194.
      Citations: 10     Fields:    Translation:HumansCells
    55. Bertucci F, Rypens C, Finetti P, Guille A, Adélaïde J, Monneur A, Carbuccia N, Garnier S, Dirix P, Gonçalves A, Vermeulen P, Debeb BG, Wang X, Dirix L, Ueno NT, Viens P, Cristofanilli M, Chaffanet M, Birnbaum D, Van Laere S. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. Mol Oncol. 2020 03; 14(3):504-519. PMID: 31854063.
      Citations: 13     Fields:    Translation:HumansCells
    56. Kogawa T, Fujii T, Wu J, Harano K, Fouad TM, Liu DD, Shen Y, Masuda H, Krishnamurthy S, Chavez-MacGregor M, Lim B, Murthy RK, Valero V, Tripathy D, Ueno NT. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist. 2020 06; 25(6):e909-e919. PMID: 32003919.
      Citations: 1     Fields:    Translation:Humans
    57. Eckhardt BL, Cao Y, Redfern AD, Chi LH, Burrows AD, Roslan S, Sloan EK, Parker BS, Loi S, Ueno NT, Lau PKH, Latham B, Anderson RL. Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. Cancer Res. 2020 03 15; 80(6):1304-1315. PMID: 31941699.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    58. Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. Cancer Med. 2020 02; 9(3):1025-1032. PMID: 31849202.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    59. Tamura K, Imamura CK, Takano T, Saji S, Yamanaka T, Yonemori K, Takahashi M, Tsurutani J, Nishimura R, Sato K, Kitani A, Ueno NT, Mushiroda T, Kubo M, Fujiwara Y, Tanigawara Y. CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. J Clin Oncol. 2020 02 20; 38(6):558-566. PMID: 31821071.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    60. Funakoshi Y, Wang Y, Semba T, Masuda H, Hout D, Ueno NT, Wang X. Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype. PLoS One. 2019; 14(9):e0222336. PMID: 31532791.
      Citations: 8     Fields:    Translation:HumansCells
    61. De Giorgi U, Mego M, Scarpi E, Giordano A, Giuliano M, Valero V, Alvarez RH, Ueno NT, Cristofanilli M, Reuben JM. Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. Ther Adv Med Oncol. 2019; 11:1758835919866065. PMID: 31452692.
      Citations: 13     
    62. Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jul; 176(1):251. PMID: 30982934.
      Citations:    Fields:    
    63. Devi GR, Hough H, Barrett N, Cristofanilli M, Overmoyer B, Spector N, Ueno NT, Woodward W, Kirkpatrick J, Vincent B, Williams KP, Finley C, Duff B, Worthy V, McCall S, Hollister BA, Palmer G, Force J, Westbrook K, Fayanju O, Suneja G, Dent SF, Hwang ES, Patierno SR, Marcom PK. Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. J Cancer. 2019; 10(15):3344-3351. PMID: 31293637.
      Citations: 6     
    64. Ning J, Fouad TM, Lin H, Sahin AA, Lucci A, Woodward WA, Krishnamurthy S, Tripathy D, Ueno NT, Shen Y. The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. J Cancer. 2019; 10(12):2635-2642. PMID: 31258771.
      Citations:    
    65. Stecklein SR, Rosso KJ, Nuanjing J, Tadros AB, Weiss A, DeSnyder SM, Kuerer HM, Teshome M, Buchholz TA, Stauder MC, Ueno NT, Lucci A, Woodward WA. Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. Pract Radiat Oncol. 2019 Nov; 9(6):402-409. PMID: 31132433.
      Citations: 1     Fields:    Translation:Humans
    66. Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer. 2019 06; 120(12):1105-1112. PMID: 31097774.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    67. Cohen EN, Fouad TM, Lee BN, Arun BK, Liu D, Tin S, Gutierrez Barrera AM, Miura T, Kiyokawa I, Yamashita J, Alvarez RH, Valero V, Woodward WA, Shen Y, Ueno NT, Cristofanilli M, Reuben JM. Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer. Breast Cancer Res Treat. 2019 Aug; 176(3):545-556. PMID: 31054033.
      Citations: 5     Fields:    Translation:Humans
    68. Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, Tsujikawa T, Coussens LM, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward WA, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA. Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunol Res. 2019 06; 7(6):1025-1035. PMID: 31043414.
      Citations: 28     Fields:    Translation:HumansCells
    69. Fujii T, Mason J, Chen A, Kuhn P, Woodward WA, Tripathy D, Newton PK, Ueno NT. Prediction of Bone Metastasis in Inflammatory Breast Cancer Using a Markov Chain Model. Oncologist. 2019 10; 24(10):1322-1330. PMID: 30952823.
      Citations: 3     Fields:    Translation:Humans
    70. Candelaria RP, Adrada BE, Wei W, Thompson AM, Santiago L, Lane DL, Huang ML, Arribas EM, Rauch GM, Symmans WF, Gilcrease MZ, Huo L, Lim B, Ueno NT, Moulder SL, Yang WT. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol. 2019 May; 114:167-174. PMID: 31005169.
      Citations: 1     Fields:    Translation:Humans
    71. Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jun; 175(2):339-351. PMID: 30826934.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    72. Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs. 2019 04; 37(2):345-351. PMID: 30610588.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    73. Tahara RK, Brewer TM, Theriault RL, Ueno NT. Bone Metastasis of Breast Cancer. Adv Exp Med Biol. 2019; 1152:105-129. PMID: 31456182.
      Citations: 20     Fields:    Translation:Humans
    74. Liu S, Li S, Wang B, Liu W, Gagea M, Chen H, Sohn J, Parinyanitikul N, Primeau T, Do KA, Vande Woude GF, Mendelsohn J, Ueno NT, Mills GB, Tripathy D, Gonzalez-Angulo AM. Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer. Mol Cancer Ther. 2019 02; 18(2):399-412. PMID: 30518672.
      Citations: 5     Fields:    Translation:HumansCells
    75. Torres-Adorno AM, Vitrac H, Qi Y, Tan L, Levental KR, Fan YY, Yang P, Chapkin RS, Eckhardt BL, Ueno NT. Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. Oncogene. 2019 03; 38(12):2135-2150. PMID: 30459358.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    76. Harano K, Wang Y, Lim B, Seitz RS, Morris SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, Rao AUK, Laere SV, Bertucci F, Woodward WA, Reuben JM, Krishnamurthy S, Ueno NT. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. PLoS One. 2018; 13(10):e0204513. PMID: 30312311.
      Citations: 18     Fields:    Translation:HumansCells
    77. Fouad TM, Ueno NT, Yu RK, Ensor JE, Alvarez RH, Krishnamurthy S, Lucci A, Reuben JM, Yang W, Willey JS, Valero V, Bondy ML, Cristofinalli M, Shete S, Woodward WA, El-Zein R. Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. PLoS One. 2018; 13(9):e0204372. PMID: 30248155.
      Citations: 7     Fields:    Translation:Humans
    78. Shen Y, Fujii T, Ueno NT, Tripathy D, Fu N, Zhou H, Ning J, Xiao L. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis. Breast Cancer Res Treat. 2019 Jan; 173(1):1-9. PMID: 30242579.
      Citations: 4     Fields:    Translation:Humans
    79. Nguyen K, Yan Y, Yuan B, Dasgupta A, Sun J, Mu H, Do KA, Ueno NT, Andreeff M, Battula VL. ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK-AKT-mTOR Signaling Pathway. Mol Cancer Ther. 2018 12; 17(12):2689-2701. PMID: 30237308.
      Citations: 32     Fields:    Translation:HumansCells
    80. Kono M, Fujii T, Matsuda N, Harano K, Chen H, Wathoo C, Joon AY, Tripathy D, Meric-Bernstam F, Ueno NT. Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. J Cancer. 2018; 9(19):3640-3646. PMID: 30310523.
      Citations: 13     
    81. Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213. PMID: 29879283.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    82. Lim B, Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT. Inflammatory breast cancer biology: the tumour microenvironment is key. Nat Rev Cancer. 2018 08; 18(8):485-499. PMID: 29703913.
      Citations: 98     Fields:    Translation:HumansCells
    83. Lim B, Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT. Author Correction: Inflammatory breast cancer biology: the tumour microenvironment is key. Nat Rev Cancer. 2018 Aug; 18(8):526. PMID: 29748602.
      Citations: 5     Fields:    
    84. Umehara H, Maekawa Y, Koizumi F, Shimizu M, Ota T, Fouad TM, Willey J, Kaito H, Shiraishi N, Nakashima D, Akinaga S, Ueno NT. Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole. Ther Adv Med Oncol. 2018; 10:1758835918786858. PMID: 30083253.
      Citations: 1     
    85. Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288. PMID: 30077429.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    86. Kai K, Iwamoto T, Zhang D, Shen L, Takahashi Y, Rao A, Thompson A, Sen S, Ueno NT. CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer. Sci Rep. 2018 06 21; 8(1):9427. PMID: 29930294.
      Citations: 11     Fields:    Translation:HumansCells
    87. Kogawa T, Fujii T, Fouad TM, Liu DD, Harano K, Masuda H, Iwase T, Barnett C, Park YS, Lim B, Tripathy D, Litton JK, Ueno NT. Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. Breast Cancer Res Treat. 2018 Sep; 171(2):501-511. PMID: 29915946.
      Citations: 3     Fields:    Translation:Humans
    88. Woodward WA, Ueno NT, Kuerer HM, Lucci A, Shen Y. Reply to 'A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18'. Breast. 2018 06; 39:148-149. PMID: 29729725.
      Citations:    Fields:    Translation:Humans
    89. Menta A, Fouad TM, Lucci A, Le-Petross H, Stauder MC, Woodward WA, Ueno NT, Lim B. Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer. Surg Clin North Am. 2018 Aug; 98(4):787-800. PMID: 30005774.
      Citations: 19     Fields:    Translation:Humans
    90. Eckhardt BL, Gagliardi M, Iles L, Evans K, Ivan C, Liu X, Liu CG, Souza G, Rao A, Meric-Bernstam F, Ueno NT, Bartholomeusz GA. Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies. PLoS One. 2018; 13(5):e0195932. PMID: 29768500.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    91. Gage MM, Mylander WC, Rosman M, Fujii T, Le Du F, Raghavendra A, Sinha AK, Espinosa Fernandez JR, James A, Ueno NT, Tafra L, Jackson RS. Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay. Ann Oncol. 2018 05 01; 29(5):1280-1285. PMID: 29788166.
      Citations: 4     Fields:    Translation:Humans
    92. Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim TB, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen K. Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol. 2018; 2018. PMID: 30035249.
      Citations: 19     Fields:    
    93. Ding Q, Wang Y, Zuo Z, Gong Y, Krishnamurthy S, Li CW, Lai YJ, Wei W, Wang J, Manyam GC, Diao L, Zhang X, Lin F, Symmans WF, Sun L, Liu CG, Liu X, Debeb BG, Ueno NT, Harano K, Alvarez RH, Wu Y, Cristofanilli M, Huo L. Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Hum Pathol. 2018 07; 77:121-129. PMID: 29689244.
      Citations: 9     Fields:    Translation:HumansCells
    94. Alexander A, Arnold TL, Bishnoi S, Ballinger C, Shaitelman SF, Schaverien MV, Cohen L, Dev M, Ueno NT. Survivorship and Advocacy in Inflammatory Breast Cancer. J Cancer. 2018; 9(8):1430-1436. PMID: 29721053.
      Citations:    
    95. Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018; 9(8):1437-1447. PMID: 29721054.
      Citations: 29     
    96. Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305. PMID: 29579338.
      Citations: 6     Fields:    Translation:Humans
    97. Weiss A, Menen RS, Lin HY, Shen Y, Rosso KJ, Shaitelman S, Woodward W, Valero V, Ueno NT, Bedrosian I, Babiera G. Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. Breast Cancer Res Treat. 2018 Jun; 169(3):615-623. PMID: 29460033.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    98. He J, Huo L, Ma J, Zhao J, Bassett RL, Sun X, Ueno NT, Lim B, Gong Y. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol. 2018 Feb 17; 149(3):253-261. PMID: 29425258.
      Citations: 10     Fields:    Translation:Humans
    99. Yamauchi T, Espinosa Fernandez JR, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Chen H, Takebe N, Saya H, Ueno NT. Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. Oncotarget. 2018 Jan 23; 9(6):6872-6882. PMID: 29467936.
      Citations: 3     Fields:    
    100. Arun BK, Gutierrez Barrera AM, Ueno NT. Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue. Cancer. 2018 02 15; 124(4):866. PMID: 29266209.
      Citations:    Fields:    Translation:Humans
    101. Fujii T, Matsuda N, Kono M, Harano K, Chen H, Luthra R, Roy-Chowdhuri S, Sahin AA, Wathoo C, Joon AY, Tripathy D, Meric-Bernstam F, Ueno NT. Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. Eur J Cancer. 2018 01; 89:64-71. PMID: 29232568.
      Citations: 2     Fields:    Translation:Humans
    102. Gutierrez Barrera AM, Fouad TM, Song J, Webster R, Elsayegh N, Wood AL, Demir A, Litton JK, Ueno NT, Arun BK. BRCA mutations in women with inflammatory breast cancer. Cancer. 2018 02 01; 124(3):466-474. PMID: 29044548.
      Citations: 5     Fields:    Translation:Humans
    103. Schvartsman G, Gutierrez-Barrera AM, Song J, Ueno NT, Peterson SK, Arun B. Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes. Cancer Med. 2017 Nov; 6(11):2515-2522. PMID: 29024537.
      Citations: 11     Fields:    Translation:Humans
    104. Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT. Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. J Cancer. 2017; 8(17):3607-3614. PMID: 29667990.
      Citations: 2     
    105. Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol. 2017 Oct 01; 28(10):2420-2428. PMID: 28961844.
      Citations: 41     Fields:    Translation:Humans
    106. Fujii T, Reuben JM, Huo L, Espinosa Fernandez JR, Gong Y, Krupa R, Suraneni MV, Graf RP, Lee J, Greene S, Rodriguez A, Dugan L, Louw J, Lim B, Barcenas CH, Marx AN, Tripathy D, Wang Y, Landers M, Dittamore R, Ueno NT. Androgen receptor expression on circulating tumor cells in metastatic breast cancer. PLoS One. 2017; 12(9):e0185231. PMID: 28957377.
      Citations: 10     Fields:    Translation:HumansCells
    107. Kono M, Fujii T, Lim B, Karuturi MS, Tripathy D, Ueno NT. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. JAMA Oncol. 2017 Sep 01; 3(9):1266-1273. PMID: 28301631.
      Citations: 76     Fields:    Translation:HumansCells
    108. Harano K, Kogawa T, Wu J, Yuan Y, Cohen EN, Lim B, Reuben JM, Ueno NT. Thrombocytosis as a prognostic factor in inflammatory breast cancer. Breast Cancer Res Treat. 2017 Dec; 166(3):819-832. PMID: 28831670.
      Citations: 9     Fields:    Translation:HumansCells
    109. Arango NP, Yuca E, Zhao M, Evans KW, Scott S, Kim C, Gonzalez-Angulo AM, Janku F, Ueno NT, Tripathy D, Akcakanat A, Naing A, Meric-Bernstam F. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res. 2017 Aug 15; 19(1):93. PMID: 28810913.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    110. Rosso KJ, Tadros AB, Weiss A, Warneke CL, DeSnyder S, Kuerer H, Ueno NT, Stecklein SR, Woodward WA, Lucci A. Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery. Ann Surg Oncol. 2017 Oct; 24(10):2981-2988. PMID: 28766220.
      Citations: 9     Fields:    Translation:Humans
    111. Masuda H, Qi Y, Liu S, Hayashi N, Kogawa T, Hortobagyi GN, Tripathy D, Ueno NT. Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. Oncotarget. 2017 Sep 19; 8(41):70481-70495. PMID: 29050296.
      Citations: 8     Fields:    
    112. DeSnyder SM, Mittendorf EA, Le-Petross C, Krishnamurthy S, Whitman GJ, Ueno NT, Woodward WA, Kuerer HM, Akay CL, Babiera GV, Yang W, Lucci A. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer. Clin Breast Cancer. 2018 02; 18(1):e73-e77. PMID: 28755879.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    113. Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer. 2017; 8(11):2004-2009. PMID: 28819400.
      Citations: 6     
    114. Shaitelman SF, Stauder MC, Allen P, Reddy S, Lakoski S, Atkinson B, Reddy J, Amaya D, Guerra W, Ueno N, Caudle A, Tereffe W, Woodward WA. Impact of Statin Use on Outcomes in Triple Negative Breast Cancer. J Cancer. 2017; 8(11):2026-2032. PMID: 28819403.
      Citations: 12     
    115. Rosso KJ, Ueno NT, Woodward WA, Lucci A. In response to "outcomes of patients with inflammatory breast cancer treated by breast conserving surgery": the argument against breast conservation and sentinel lymph node biopsy in IBC. Breast Cancer Res Treat. 2017 10; 165(3):779-781. PMID: 28674763.
      Citations:    Fields:    Translation:Humans
    116. Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT, Fouad TM. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Ther Adv Med Oncol. 2017 Jul; 9(7):493-511. PMID: 28717401.
      Citations: 24     
    117. Joglekar-Javadekar M, Van Laere S, Bourne M, Moalwi M, Finetti P, Vermeulen PB, Birnbaum D, Dirix LY, Ueno N, Carter M, Rains J, Ramachandran A, Bertucci F, van Golen KL. Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC). Neoplasia. 2017 Jul; 19(7):564-573. PMID: 28609680.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    118. Sato N, Wakabayashi M, Nakatsuji M, Kashiwagura H, Shimoji N, Sakamoto S, Ishida A, Lee J, Lim B, Ueno NT, Ishihara H, Inui T. MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer. Biochem Biophys Res Commun. 2017 08 05; 489(4):484-489. PMID: 28576487.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    119. Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Tin S, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget. 2017 May 30; 8(22):35656-35668. PMID: 27374101.
      Citations: 21     Fields:    Translation:HumansCells
    120. Daquinag AC, Dadbin A, Snyder B, Wang X, Sahin AA, Ueno NT, Kolonin MG. Non-glycanated Decorin Is a Drug Target on Human Adipose Stromal Cells. Mol Ther Oncolytics. 2017 Sep 15; 6:1-9. PMID: 28607949.
      Citations: 17     
    121. Harao M, Forget MA, Roszik J, Gao H, Babiera GV, Krishnamurthy S, Chacon JA, Li S, Mittendorf EA, DeSnyder SM, Rockwood KF, Bernatchez C, Ueno NT, Radvanyi LG, Vence L, Haymaker C, Reuben JM. 4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells. Cancer Immunol Res. 2017 06; 5(6):439-445. PMID: 28473315.
      Citations: 18     Fields:    Translation:HumansCells
    122. Torres-Adorno AM, Lee J, Kogawa T, Ordentlich P, Tripathy D, Lim B, Ueno NT. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. Clin Cancer Res. 2017 Aug 15; 23(16):4780-4792. PMID: 28465444.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    123. Reyes ME, Fujii T, Branstetter D, Krishnamurthy S, Masuda H, Wang X, Reuben JM, Woodward WA, Edwards BJ, Hortobagyi GN, Tripathy D, Dougall WC, Eckhardt BL, Ueno NT. Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Res Treat. 2017 Jul; 164(1):57-67. PMID: 28417335.
      Citations: 11     Fields:    Translation:Humans
    124. Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Yamauchi H, Nakamura S, Hortobagyi GN, Pusztai L, Symmans WF, Ueno NT. Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. J Cancer. 2017; 8(6):1045-1052. PMID: 28529618.
      Citations: 6     
    125. Fouad TM, Barrera AMG, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT. Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncol. 2017 04; 18(4):e228-e232. PMID: 28368261.
      Citations: 43     Fields:    Translation:Humans
    126. Cheng YC, Shi Y, Zhang MJ, Brazauskas R, Hemmer MT, Bishop MR, Nieto Y, Stadtmauer E, Ayash L, Gale RP, Lazarus H, Holmberg L, Lill M, Olsson RF, Wirk BM, Arora M, Hari P, Ueno N. Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. J Cancer. 2017; 8(6):1009-1017. PMID: 28529613.
      Citations: 3     
    127. Fujii T, Ueno NT. Reply to 'Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''. Br J Cancer. 2017 04 11; 116(8):e11. PMID: 28291772.
      Citations:    Fields:    Translation:Humans
    128. Lin HY, Bedrosian I, Babiera GV, Shaitelman SF, Kuerer HM, Woodward WA, Ueno NT, Shen Y. Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer. 2017 Jul 15; 123(14):2618-2625. PMID: 28295213.
      Citations: 4     Fields:    Translation:Humans
    129. Matsuda N, Lim B, Wang X, Ueno NT. Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. Expert Opin Investig Drugs. 2017 Apr; 26(4):463-479. PMID: 28271910.
      Citations: 21     Fields:    Translation:HumansAnimals
    130. Alexander A, Karakas C, Chen X, Carey JP, Yi M, Bondy M, Thompson P, Cheung KL, Ellis IO, Gong Y, Krishnamurthy S, Alvarez RH, Ueno NT, Hunt KK, Keyomarsi K. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget. 2017 Feb 28; 8(9):14897-14911. PMID: 28107181.
      Citations: 17     Fields:    Translation:HumansCells
    131. Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH, Lucci A, Valero V, Reuben JM, Meric-Bernstam F, Ueno NT. Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat. 2017 Jun; 163(2):263-272. PMID: 28243898.
      Citations: 15     Fields:    Translation:Humans
    132. Barcenas CH, Raghavendra A, Sinha AK, Syed MP, Hsu L, Patangan MG, Chavez-MacGregor M, Shen Y, Hortobagyi GH, Valero V, Giordano SH, Ueno NT, Tripathy D. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Cancer. 2017 Jul 01; 123(13):2422-2431. PMID: 28199747.
      Citations: 13     Fields:    Translation:Humans
    133. Sinha AK, Patel JR, Shen Y, Ueno NT, Giordano SH, Tripathy D, Lopez DS, Barcenas CH. Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors. PLoS One. 2017; 12(1):e0170081. PMID: 28085940.
      Citations: 4     Fields:    Translation:Humans
    134. Fujii T, Kogawa T, Wu J, Sahin AA, Liu DD, Chavez-MacGregor M, Giordano SH, Raghavendra A, Murthy RK, Tripathy D, Shen Y, Yamal JM, Ueno NT. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Br J Cancer. 2017 Feb 14; 116(4):509-514. PMID: 28081544.
      Citations: 9     Fields:    Translation:Humans
    135. Wolfe AR, Trenton NJ, Debeb BG, Larson R, Ruffell B, Chu K, Hittelman W, Diehl M, Reuben JM, Ueno NT, Woodward WA. Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. Oncotarget. 2016 Dec 13; 7(50):82482-82492. PMID: 27756885.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    136. Xie X, Kaoud TS, Edupuganti R, Zhang T, Kogawa T, Zhao Y, Chauhan GB, Giannoukos DN, Qi Y, Tripathy D, Wang J, Gray NS, Dalby KN, Bartholomeusz C, Ueno NT. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun. Oncogene. 2017 05 04; 36(18):2599-2608. PMID: 27941886.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    137. Basho RK, de Melo Gagliato D, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 2016 Nov 22; 7(47):76362-76373. PMID: 27806348.
      Citations: 12     Fields:    Translation:Humans
    138. Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardó-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WHP, Hajitou A, Lomo LC, Barry M, Krishnamurthy S, Sahin A, Woodward WA, Prossnitz ER, Anderson RL, Dias-Neto E, Brown-Glaberman UA, Royce ME, Ueno NT, Cristofanilli M, Hortobagyi GN, Marchiò S, Gelovani JG, Sidman RL, Arap W, Pasqualini R. Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proc Natl Acad Sci U S A. 2016 Nov 08; 113(45):12780-12785. PMID: 27791177.
      Citations: 22     Fields:    
    139. Kono M, Fujii T, Lyons GR, Huo L, Bassett R, Gong Y, Karuturi MS, Tripathy D, Ueno NT. Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. Breast Cancer Res Treat. 2016 11; 160(1):101-109. PMID: 27663436.
      Citations: 5     Fields:    Translation:Humans
    140. Treekitkarnmongkol W, Katayama H, Kai K, Sasai K, Jones JC, Wang J, Shen L, Sahin AA, Gagea M, Ueno NT, Creighton CJ, Sen S. Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer. Carcinogenesis. 2016 Dec; 37(12):1180-1189. PMID: 27624071.
      Citations: 15     Fields:    Translation:HumansAnimals
    141. Le Du F, Fujii T, Park M, Liu D, Hsu L, Gonzalez-Angulo AM, Ueno NT. Impact of clinical trial on survival outcomes. Breast Cancer Res Treat. 2016 Sep; 159(2):273-81. PMID: 27530453.
      Citations: 1     Fields:    Translation:Humans
    142. Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez-MacGregor M. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016 Sep; 159(2):367-74. PMID: 27522517.
      Citations: 6     Fields:    Translation:Humans
    143. Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Sanda T, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. J Cancer. 2016; 7(9):1095-104. PMID: 27326253.
      Citations: 37     
    144. Trapé AP, Liu S, Cortes AC, Ueno NT, Gonzalez-Angulo AM. Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel. J Cancer. 2016; 7(8):947-56. PMID: 27313785.
      Citations: 5     
    145. Debeb BG, Lacerda L, Larson R, Wolfe AR, Krishnamurthy S, Reuben JM, Ueno NT, Gilcrease M, Woodward WA. Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget. 2016 May 10; 7(19):28329-39. PMID: 27078845.
      Citations: 25     Fields:    Translation:HumansCells
    146. Debeb BG, Lacerda L, Anfossi S, Diagaradjane P, Chu K, Bambhroliya A, Huo L, Wei C, Larson RA, Wolfe AR, Xu W, Smith DL, Li L, Ivan C, Allen PK, Wu W, Calin GA, Krishnamurthy S, Zhang XH, Buchholz TA, Ueno NT, Reuben JM, Woodward WA. miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. J Natl Cancer Inst. 2016 08; 108(8). PMID: 27075851.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    147. Ueno NT, Mamounas EP. Neoadjuvant nab-paclitaxel in the treatment of breast cancer. Breast Cancer Res Treat. 2016 Apr; 156(3):427-440. PMID: 27072366.
      Citations: 9     Fields:    Translation:Humans
    148. Chae YK, Gagliato Dde M, Pai SG, Carneiro B, Mohindra N, Giles FJ, Ramakrishnan-Geethakumari P, Sohn J, Liu S, Chen H, Ueno N, Hortobagyi G, Gonzalez-Angulo AM. The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. PLoS One. 2016; 11(4):e0152585. PMID: 27055285.
      Citations: 9     Fields:    Translation:HumansCells
    149. Tabouret E, Bertucci F, Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, van Laere S, Ueno NT, Toiron Y, Finetti P, Birnbaum D, Borg JP, Viens P, Chinot O, Gonçalves A. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget. 2016 Apr 05; 7(14):18531-40. PMID: 26921265.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    150. Loveland-Jones C, Lin H, Shen Y, Bedrosian I, Shaitelman S, Kuerer H, Woodward W, Ueno N, Valero V, Babiera G. Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1218-25. PMID: 27209502.
      Citations: 2     Fields:    Translation:Humans
    151. Huo L, Wang Y, Gong Y, Krishnamurthy S, Wang J, Diao L, Liu CG, Liu X, Lin F, Symmans WF, Wei W, Zhang X, Sun L, Alvarez RH, Ueno NT, Fouad TM, Harano K, Debeb BG, Wu Y, Reuben J, Cristofanilli M, Zuo Z. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol. 2016 Apr; 29(4):330-46. PMID: 26916073.
      Citations: 16     Fields:    Translation:Humans
    152. Atkinson RL, El-Zein R, Valero V, Lucci A, Bevers TB, Fouad T, Liao W, Ueno NT, Woodward WA, Brewster AM. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control. 2016 Mar; 27(3):359-66. PMID: 26797453.
      Citations: 15     Fields:    Translation:Humans
    153. Raghav K, French JT, Ueno NT, Lei X, Krishnamurthy S, Reuben JM, Valero V, Ibrahim NK. Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction. PLoS One. 2016; 11(1):e0145534. PMID: 26752563.
      Citations: 8     Fields:    Translation:Humans
    154. Kogawa T, Fouad TM, Liu DD, Wu J, Shen Y, Masuda H, Fujii T, Chavez-MacGregor M, Alvarez RH, Hortobágyi GN, Valero V, Ueno NT. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist. 2016 Jan; 21(1):21-7. PMID: 26659222.
      Citations: 9     Fields:    Translation:HumansCells
    155. Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2015 Dec; 1(9):1311-8. PMID: 26402167.
      Citations: 28     Fields:    Translation:Humans
    156. Wolfe AR, Debeb BG, Lacerda L, Larson R, Bambhroliya A, Huang X, Bertucci F, Finetti P, Birnbaum D, Van Laere S, Diagaradjan P, Ruffell B, Trenton NJ, Chu K, Hittelman W, Diehl M, Levental I, Ueno NT, Woodward WA. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Res Treat. 2015 Dec; 154(3):495-508. PMID: 26590814.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    157. Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C, Goodstal S, Lim B, Bartholomeusz G, Ueno NT, Rao A. Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. J Cancer. 2015; 6(12):1306-19. PMID: 26640591.
      Citations: 9     
    158. Kai K, Kondo K, Wang X, Xie X, Pitner MK, Reyes ME, Torres-Adorno AM, Masuda H, Hortobagyi GN, Bartholomeusz C, Saya H, Tripathy D, Sen S, Ueno NT. Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Mol Cancer Ther. 2015 Dec; 14(12):2687-99. PMID: 26443806.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    159. Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Dalby KN, Ueno NT. MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. Mol Cancer Ther. 2015 Dec; 14(12):2773-81. PMID: 26384399.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    160. Bishop AJ, Ensor J, Moulder SL, Shaitelman SF, Edson MA, Whitman GJ, Bishnoi S, Hoffman KE, Stauder MC, Valero V, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer. 2015 Dec 15; 121(24):4324-32. PMID: 26348887.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    161. Ning J, Peng S, Ueno N, Xu Y, Shih Y, Karuturi M, Giordano S, Shen Y. Has racial difference in cause-specific death improved in older patients with late-stage breast cancer? Ann Oncol. 2015 Oct; 26(10):2161-8. PMID: 26223248.
      Citations: 6     Fields:    Translation:Humans
    162. Cohen EN, Gao H, Anfossi S, Mego M, Reddy NG, Debeb B, Giordano A, Tin S, Wu Q, Garza RJ, Cristofanilli M, Mani SA, Croix DA, Ueno NT, Woodward WA, Luthra R, Krishnamurthy S, Reuben JM. Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. PLoS One. 2015; 10(7):e0132710. PMID: 26207636.
      Citations: 52     Fields:    Translation:HumansCells
    163. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. PMID: 26211600.
      Citations: 44     Fields:    Translation:Humans
    164. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):417. PMID: 26092296.
      Citations: 1     Fields:    
    165. Kato S, Moulder SL, Ueno NT, Wheler JJ, Meric-Bernstam F, Kurzrock R, Janku F. Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience. 2015; 2(6):576-80. PMID: 26244164.
      Citations: 12     
    166. Le Du F, Gonzalez-Angulo AM, Park M, Liu DD, Hortobagyi GN, Ueno NT. Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer. Clin Breast Cancer. 2015 Dec; 15(6):458-66. PMID: 26233757.
      Citations: 5     Fields:    Translation:Humans
    167. Tsai CJ, Li J, Gonzalez-Angulo AM, Allen PK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Yang W, Cristofanilli M, Valero V, Buchholz TA. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. Am J Clin Oncol. 2015 Jun; 38(3):242-7. PMID: 23648437.
      Citations: 9     Fields:    Translation:Humans
    168. Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget. 2015 May 30; 6(15):12890-908. PMID: 25973541.
      Citations: 45     Fields:    Translation:Humans
    169. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):407-16. PMID: 26017070.
      Citations: 30     Fields:    Translation:Humans
    170. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62. PMID: 26014291.
      Citations: 203     Fields:    Translation:Humans
    171. Wolfe AR, Atkinson RL, Reddy JP, Debeb BG, Larson R, Li L, Masuda H, Brewer T, Atkinson BJ, Brewster A, Ueno NT, Woodward WA. High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2015 Apr 01; 91(5):1072-80. PMID: 25832697.
      Citations: 10     Fields:    Translation:HumansCells
    172. Lacerda L, Debeb BG, Smith D, Larson R, Solley T, Xu W, Krishnamurthy S, Gong Y, Levy LB, Buchholz T, Ueno NT, Klopp A, Woodward WA. Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. Breast Cancer Res. 2015 Mar 20; 17:42. PMID: 25887413.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    173. Allensworth JL, Evans MK, Bertucci F, Aldrich AJ, Festa RA, Finetti P, Ueno NT, Safi R, McDonnell DP, Thiele DJ, Van Laere S, Devi GR. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. Mol Oncol. 2015 Jun; 9(6):1155-68. PMID: 25769405.
      Citations: 64     Fields:    Translation:HumansCells
    174. Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 2015 Feb 20; 6(5):2604-14. PMID: 25605252.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    175. Chang EI, Chang EI, Ito R, Zhang H, Nguyen AT, Skoracki RJ, Hanasono MM, Crosby MA, Ueno NT, Hunt KK. Challenging a traditional paradigm: 12-year experience with autologous free flap breast reconstruction for inflammatory breast cancer. Plast Reconstr Surg. 2015 Feb; 135(2):262e-269e. PMID: 25626809.
      Citations: 4     Fields:    Translation:Humans
    176. Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT. Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. J Cancer. 2015; 6(4):310-8. PMID: 25767600.
      Citations: 8     
    177. Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, Andreopoulou E, Alvarez RH, Woodward WA, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res. 2015 Jan 09; 17:2. PMID: 25572591.
      Citations: 19     Fields:    Translation:HumansCells
    178. Le Du F, Ueno NT. Targeted therapies in triple-negative breast cancer: failure and future. Womens Health (Lond). 2015 Jan; 11(1):1-5. PMID: 25581048.
      Citations: 2     Fields:    Translation:Humans
    179. Mego M, Zuo Z, Gao H, Cohen EN, Giordano A, Tin S, Anfossi S, Jackson S, Woodward W, Ueno NT, Valero V, Alvarez RH, Hortobagyi GN, Khoury JD, Cristofanilli M, Reuben JM. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thromb Haemost. 2015 Mar; 113(3):593-8. PMID: 25373787.
      Citations: 14     Fields:    Translation:HumansCells
    180. Sohn J, Liu S, Parinyanitikul N, Lee J, Hortobagyi GN, Mills GB, Ueno NT, Gonzalez-Angulo AM. cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. J Cancer. 2014; 5(9):745-53. PMID: 25368674.
      Citations: 21     
    181. Xie X, Tang H, Kong Y, Wu M, Xiao X, Yang L, Gao J, Wei W, Lee J, Bartholomeusz C, Ueno NT, Xie X. Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Lett. 2015 Jan 28; 356(2 Pt B):374-381. PMID: 25304382.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    182. Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res. 2014 Sep 16; 16(5):440. PMID: 25223629.
      Citations: 43     Fields:    Translation:HumansCells
    183. Pusztai L, Moulder S, Altan M, Kwiatkowski D, Valero V, Ueno NT, Esteva FJ, Avritscher R, Qi Y, Strauss L, Hortobagyi GN, Hatzis C, Symmans WF. Gene signature-guided dasatinib therapy in metastatic breast cancer. Clin Cancer Res. 2014 Oct 15; 20(20):5265-71. PMID: 25172932.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    184. Kai M, Kogawa T, Liu DD, Fouad TM, Kai K, Niikura N, Hsu L, Willey JS, Theriault RL, Valero V, Ueno NT. Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers. Clin Breast Cancer. 2015 Feb; 15(1):37-42. PMID: 25258308.
      Citations: 3     Fields:    Translation:Humans
    185. Hayashi N, Manyam GC, Gonzalez-Angulo AM, Niikura N, Yamauchi H, Nakamura S, Hortobágyi GN, Baggerly KA, Ueno NT. Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer. Oncologist. 2014 Sep; 19(9):909-14. PMID: 25117064.
      Citations: 6     Fields:    Translation:Humans
    186. Debeb BG, Gong Y, Atkinson RL, Sneige N, Huo L, Gonzalez-Angulo AM, Hung MC, Valero V, Ueno NT, Woodward WA. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. J Exp Clin Cancer Res. 2014 Jul 23; 33:58. PMID: 25051981.
      Citations: 11     Fields:    Translation:Humans
    187. Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NT. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat. 2014 Jul; 146(2):259-72. PMID: 24916181.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    188. Rueth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, Babiera G. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. J Clin Oncol. 2014 Jul 01; 32(19):2018-24. PMID: 24888808.
      Citations: 40     Fields:    Translation:Humans
    189. Lacerda L, Reddy JP, Liu D, Larson R, Li L, Masuda H, Brewer T, Debeb BG, Xu W, Hortobágyi GN, Buchholz TA, Ueno NT, Woodward WA. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med. 2014 Jul; 3(7):849-56. PMID: 24833589.
      Citations: 32     Fields:    Translation:HumansCells
    190. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep. 2014 Apr 24; 7(2):488-500. PMID: 24703838.
      Citations: 26     Fields:    Translation:HumansCells
    191. Takiar V, Akay CL, Stauder MC, Tereffe W, Alvarez RH, Hoffman KE, Perkins GH, Strom EA, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. Springerplus. 2014; 3:166. PMID: 24711988.
      Citations: 2     
    192. Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN, Woodward WA, Alvarez RH, Bedrosian I, Kuerer HM, Hunt KK, Huo L, Babiera GV. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer. 2014 May 01; 120(9):1319-28. PMID: 24510381.
      Citations: 16     Fields:    Translation:Humans
    193. Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, Garza RJ, Debeb BG, Alvarez RH, Valero V, Hortobagyi GN, Calin GA, Ueno NT, Woodward WA, Reuben JM. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One. 2014; 9(1):e83113. PMID: 24416156.
      Citations: 38     Fields:    Translation:HumansCells
    194. Gong Y, Wang J, Huo L, Wei W, Ueno NT, Woodward WA. Aldehyde dehydrogenase 1 expression in inflammatory breast cancer as measured by immunohistochemical staining. Clin Breast Cancer. 2014 Jun; 14(3):e81-8. PMID: 24461456.
      Citations: 6     Fields:    Translation:HumansCells
    195. Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol. 2014 Feb; 25(2):384-91. PMID: 24351399.
      Citations: 49     Fields:    Translation:Humans
    196. Bertucci F, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, Van Dam P, Woodward WA, Cristofanilli M, Reuben JM, Dirix L, Viens P, Symmans WF, Birnbaum D, Van Laere SJ. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol. 2014 Feb; 25(2):358-65. PMID: 24299959.
      Citations: 47     Fields:    Translation:HumansCells
    197. Le Du F, Ueno NT, Gonzalez-Angulo AM. Breast Cancer Biomarkers: Utility in Clinical Practice. Curr Breast Cancer Rep. 2013 Dec; 5(4). PMID: 24416469.
      Citations: 5     
    198. Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, Reuben JM, Krishnamurthy S, Symmans W, Van Laere SJ, Bertucci F, Hortobagyi GN, Ueno NT. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res. 2013 Nov 25; 15(6):R112. PMID: 24274653.
      Citations: 27     Fields:    Translation:Humans
    199. Torikoshi Y, Gohda K, Davis ML, Symmans WF, Pusztai L, Kazansky A, Nakayama S, Yoshida T, Matsushima T, Hortobagyi GN, Ishihara H, Kim SJ, Noguchi S, Ueno NT. Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient. J Cancer. 2013; 4(9):697-702. PMID: 24312139.
      Citations: 3     
    200. Niikura N, Odisio BC, Tokuda Y, Symmans FW, Hortobagyi GN, Ueno NT. Latest biopsy approach for suspected metastases in patients with breast cancer. Nat Rev Clin Oncol. 2013 Dec; 10(12):711-9. PMID: 24145987.
      Citations: 3     Fields:    Translation:Humans
    201. Natori A, Hayashi N, Soejima K, Deshpande GA, Takahashi O, Cristofanilli M, Ueno NT, Yamauchi H. A comparison of epidemiology, biology, and prognosis of inflammatory breast cancer in Japanese and US populations. Clin Breast Cancer. 2013 Dec; 13(6):460-4. PMID: 24084032.
      Citations: 4     Fields:    Translation:HumansCells
    202. Cheng YC, Rondón G, Anderlini P, Khouri IF, Champlin RE, Ueno NT. Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. J Cancer. 2013; 4(8):679-85. PMID: 24155780.
      Citations: 2     
    203. Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res. 2013 Nov 01; 73(21):6516-25. PMID: 24014597.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    204. Krishnamurthy S, Woodward W, Yang W, Reuben JM, Tepperberg J, Ogura D, Niwa S, Huo L, Gong Y, El-Zein R, Gonzalez-Angulo AM, Chavez-Macgregor M, Alvarez R, Lucci A, Valero V, Ueno NT. Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. Springerplus. 2013; 2:409. PMID: 24156086.
      Citations: 8     
    205. Xu W, Lacerda L, Debeb BG, Atkinson RL, Solley TN, Li L, Orton D, McMurray JS, Hang BI, Lee E, Klopp AH, Ueno NT, Reuben JM, Krishnamurthy S, Woodward WA. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS One. 2013; 8(8):e71508. PMID: 24013655.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    206. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013 Oct 01; 19(19):5533-40. PMID: 23948975.
      Citations: 290     Fields:    Translation:Humans
    207. Zhang W, Kai K, Ueno NT, Qin L. A Brief Review of the Biophysical Hallmarks of Metastatic Cancer Cells. Cancer Hallm. 2013 Aug; 1(2-3):59-66. PMID: 25309822.
      Citations: 7     
    208. Carkaci S, Sherman CT, Ozkan E, Adrada BE, Wei W, Rohren EM, Mawlawi OR, Ueno NT, Buchholz TA, Yang WT. (18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2013 Dec; 40(12):1809-16. PMID: 23877633.
      Citations: 6     Fields:    Translation:Humans
    209. Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T, Kai K, Barnett CM, Woodward WA, Reuben JM, Yang P, Hortobagyi GN, Ueno NT. Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer. 2013 Jul 23; 109(2):318-24. PMID: 23820253.
      Citations: 40     Fields:    Translation:Humans
    210. Sowers LP, Loo L, Wu Y, Campbell E, Ulrich JD, Wu S, Paemka L, Wassink T, Meyer K, Bing X, El-Shanti H, Usachev YM, Ueno N, Manak JR, Manak RJ, Shepherd AJ, Ferguson PJ, Darbro BW, Richerson GB, Mohapatra DP, Wemmie JA, Bassuk AG. Disruption of the non-canonical Wnt gene PRICKLE2 leads to autism-like behaviors with evidence for hippocampal synaptic dysfunction. Mol Psychiatry. 2013 Oct; 18(10):1077-89. PMID: 23711981.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    211. Woodward WA, Krishnamurthy S, Yamauchi H, El-Zein R, Ogura D, Kitadai E, Niwa S, Cristofanilli M, Vermeulen P, Dirix L, Viens P, van Laere S, Bertucci F, Reuben JM, Ueno NT. Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(3):761-72. PMID: 23568481.
      Citations: 20     Fields:    Translation:Humans
    212. Xie X, Bartholomeusz C, Ahmed AA, Kazansky A, Diao L, Baggerly KA, Hortobagyi GN, Ueno NT. Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP. Mol Cancer Ther. 2013 Jun; 12(6):1099-111. PMID: 23543364.
      Citations: 10     Fields:    Translation:HumansCells
    213. Hale GA, Arora M, Ahn KW, He W, Camitta B, Bishop MR, Bitan M, Cairo MS, Chan K, Childs RW, Copelan E, Davies SM, Perez MA, Doyle JJ, Gale RP, Vicent MG, Horn BN, Hussein AA, Jodele S, Kamani NR, Kasow KA, Kletzel M, Lazarus HM, Lewis VA, Myers KC, Olsson R, Pulsipher M, Qayed M, Sanders JE, Shaw PJ, Soni S, Stiff PJ, Stadtmauer EA, Ueno NT, Wall DA, Grupp SA. Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. Bone Marrow Transplant. 2013 Aug; 48(8):1056-64. PMID: 23419433.
      Citations: 2     Fields:    Translation:Humans
    214. Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, van Dam P, Woodward WA, Viens P, Cristofanilli M, Birnbaum D, Dirix L, Reuben JM, Bertucci F. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res. 2013 Sep 01; 19(17):4685-96. PMID: 23396049.
      Citations: 70     Fields:    Translation:HumansCells
    215. Kai K, Iwamoto T, Kobayashi T, Arima Y, Takamoto Y, Ohnishi N, Bartholomeusz C, Horii R, Akiyama F, Hortobagyi GN, Pusztai L, Saya H, Ueno NT. Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells. Oncogene. 2014 Jan 23; 33(4):440-8. PMID: 23376849.
      Citations: 5     Fields:    Translation:AnimalsCells
    216. Hayashi N, Niikura N, Yamauchi H, Nakamura S, Ueno NT. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):523-31. PMID: 23184079.
      Citations: 11     Fields:    Translation:Humans
    217. Debeb BG, Lacerda L, Xu W, Larson R, Solley T, Atkinson R, Sulman EP, Ueno NT, Krishnamurthy S, Reuben JM, Buchholz TA, Woodward WA. Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/ß-catenin signaling. Stem Cells. 2012 Nov; 30(11):2366-77. PMID: 22961641.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    218. Zhang W, Kai K, Choi DS, Iwamoto T, Nguyen YH, Wong H, Landis MD, Ueno NT, Chang J, Qin L. Microfluidics separation reveals the stem-cell-like deformability of tumor-initiating cells. Proc Natl Acad Sci U S A. 2012 Nov 13; 109(46):18707-12. PMID: 23112172.
      Citations: 82     Fields:    Translation:HumansCells
    219. Hayashi N, Costelloe CM, Hamaoka T, Wei C, Niikura N, Theriault RL, Hortobagyi GN, Madewell JE, Ueno NT. A prospective study of bone tumor response assessment in metastatic breast cancer. Clin Breast Cancer. 2013 Feb; 13(1):24-30. PMID: 23098575.
      Citations: 12     Fields:    Translation:Humans
    220. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):331-45. PMID: 23073759.
      Citations: 233     Fields:    Translation:Humans
    221. Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther. 2012 Nov; 11(11):2526-34. PMID: 22973057.
      Citations: 97     Fields:    Translation:HumansCells
    222. Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, Wu Q, Liu P, Nieto Y, Champlin RE, Hortobagyi GN, Cristofanilli M, Ueno NT, Reuben JM. Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer. 2012; 3:369-80. PMID: 23074378.
      Citations: 32     
    223. Lee J, Bartholomeusz C, Krishnamurthy S, Liu P, Saso H, Lafortune TA, Hortobagyi GN, Ueno NT. PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking ß-catenin. Oncogenesis. 2012 Jul 16; 1:e22. PMID: 23552738.
      Citations: 19     
    224. Alvarez RH, Gong Y, Ueno NT, Alizadeh PA, Hortobagyi GN, Valero V. Metastasis in the breast mimicking inflammatory breast cancer. J Clin Oncol. 2012 Aug 01; 30(22):e202-6. PMID: 22734030.
      Citations: 2     Fields:    Translation:Humans
    225. Saji S, Sato F, Ueno NT. Fuel, electricity, ER and HER2--a hybrid-car model of breast cancer. Nat Rev Clin Oncol. 2012 Jun 05; 9(7). PMID: 22665363.
      Citations: 3     Fields:    Translation:Humans
    226. Tada K, Kurosawa S, Hiramoto N, Okinaka K, Ueno N, Asakura Y, Kim SW, Yamashita T, Mori SI, Heike Y, Maeshima AM, Tanosaki R, Tobinai K, Fukuda T. Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage. Bone Marrow Transplant. 2013 Jan; 48(1):74-9. PMID: 22635245.
      Citations: 16     Fields:    Translation:HumansCells
    227. De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer. 2012 Aug; 12(4):264-9. PMID: 22591634.
      Citations: 46     Fields:    Translation:HumansCells
    228. Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Hortobágyi GN, Ueno NT. Inflammatory breast cancer: what we know and what we need to learn. Oncologist. 2012; 17(7):891-9. PMID: 22584436.
      Citations: 49     Fields:    Translation:Humans
    229. Cook RJ, Wang Z, Arora M, Lazarus HM, Kasow KA, Champagne MA, Saber W, van Besien KM, Hale GA, Copelan EA, Elmongy M, Ueno NT, Horn BN, Slavin S, Bishop MR, Stadtmauer EA. Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis. Bone Marrow Transplant. 2012 Nov; 47(11):1455-8. PMID: 22465977.
      Citations: 8     Fields:    Translation:Humans
    230. Simón J, Frank RK, Crump DK, Erwin WD, Ueno NT, Wendt RE. A preclinical investigation of the saturation and dosimetry of 153Sm-DOTMP as a bone-seeking radiopharmaceutical. Nucl Med Biol. 2012 Aug; 39(6):770-6. PMID: 22459336.
      Citations: 3     Fields:    Translation:HumansAnimals
    231. Ando K, Fujiya M, Ito T, Sugiyama R, Nata T, Nomura Y, Ueno N, Kashima S, Ishikawa C, Inaba Y, Moriichi K, Okamoto K, Ikuta K, Tanabe H, Tokusashi Y, Miyokawa N, Watari J, Mizukami Y, Kohgo Y. A pseudosarcomatous lesion resembling a malignant tumor of the esophagocardiac junction, diagnosed by a total biopsy with endoscopic surgery. Endoscopy. 2012; 44 Suppl 2 UCTN:E21-2. PMID: 22396258.
      Citations:    Fields:    Translation:Humans
    232. Dutta B, Pusztai L, Qi Y, André F, Lazar V, Bianchini G, Ueno N, Agarwal R, Wang B, Shiang CY, Hortobagyi GN, Mills GB, Symmans WF, Balázsi G. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. Br J Cancer. 2012 Mar 13; 106(6):1107-16. PMID: 22343619.
      Citations: 29     Fields:    Translation:HumansCells
    233. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012 Mar 01; 30(7):729-34. PMID: 22291085.
      Citations: 92     Fields:    Translation:Humans
    234. Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, Alvarez RH, Lucci A, Ueno NT, Buchholz TA. Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1381-6. PMID: 22284689.
      Citations: 8     Fields:    Translation:Humans
    235. Cheng YC, Takagi M, Milbourne A, Champlin RE, Ueno NT. Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients. Oncologist. 2012; 17(2):233-8. PMID: 22282904.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    236. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS, Jones R, Popat UR, Hosing CM, Nieto Y, Qazilbash MH, Ueno NT, Giralt SA, de Lima MJ, Champlin RE. Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leuk Lymphoma. 2012 Jun; 53(6):1239-41. PMID: 22132837.
      Citations: 4     Fields:    Translation:Humans
    237. Song Y, Zhang Y, Bernard PE, Reuben JM, Ueno NT, Arlinghaus RB, Zu Y, Qin L. Multiplexed volumetric bar-chart chip for point-of-care diagnostics. Nat Commun. 2012; 3:1283. PMID: 23250413.
      Citations: 46     Fields:    Translation:Humans
    238. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011; 16(12):1675-83. PMID: 22147002.
      Citations: 42     Fields:    Translation:Humans
    239. Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K, Kazansky A, Krishnamurthy S, Lee J, Esteva FJ, Kigawa J, Ueno NT. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther. 2012 Feb; 11(2):360-9. PMID: 22144664.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    240. Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, Ueno NT, Theriault RL. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. Cancer. 2012 Apr 15; 118(8):2039-47. PMID: 22139648.
      Citations: 9     Fields:    Translation:Humans
    241. Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012 Feb 20; 30(6):593-9. PMID: 22124109.
      Citations: 148     Fields:    Translation:Humans
    242. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol. 2012 May; 23(5):1144-1150. PMID: 21965473.
      Citations: 48     Fields:    Translation:HumansCells
    243. Bartholomeusz C, Yamasaki F, Saso H, Kurisu K, Hortobagyi GN, Ueno NT. Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt. J Cancer. 2011; 2:435-42. PMID: 21850211.
      Citations: 11     
    244. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, Yancey LJ, Crump M, Stadtmauer EA, Biron P, Crown JP, Schmid P, Lotz JP, Rosti G, Bregni M, Demirer T. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol. 2011 Aug 20; 29(24):3224-31. PMID: 21768454.
      Citations: 27     Fields:    Translation:Humans
    245. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol. 2011 Aug 20; 29(24):3214-23. PMID: 21768471.
      Citations: 32     Fields:    Translation:Humans
    246. Niikura N, Costelloe CM, Madewell JE, Hayashi N, Yu TK, Liu J, Palla SL, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT. FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist. 2011; 16(8):1111-9. PMID: 21765193.
      Citations: 18     Fields:    Translation:Humans
    247. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Identifying factors that impact survival among women with inflammatory breast cancer. Ann Oncol. 2012 Apr; 23(4):870-5. PMID: 21765048.
      Citations: 20     Fields:    Translation:Humans
    248. Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer. 2011 Dec 15; 117(24):5476-84. PMID: 21713757.
      Citations: 35     Fields:    Translation:Humans
    249. Hayashi N, Iwamoto T, Gonzalez-Angulo AM, Ferrer-Lozano J, Lluch A, Niikura N, Bartholomeusz C, Nakamura S, Hortobagyi GN, Ueno NT. Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. Oncologist. 2011; 16(7):956-65. PMID: 21712485.
      Citations: 8     Fields:    Translation:HumansCells
    250. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011 Jun 15; 13(3):R67. PMID: 21699723.
      Citations: 93     Fields:    Translation:HumansCells
    251. Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol. 2012 Apr; 17(2):96-104. PMID: 21671160.
      Citations: 37     Fields:    Translation:HumansCells
    252. Itamochi H, Yoshida T, Walker CL, Bartholomeusz C, Aoki D, Ishihara H, Suzuki N, Kigawa J, Terakawa N, Ueno NT. Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol. 2011 Sep; 122(3):641-7. PMID: 21652059.
      Citations: 12     Fields:    Translation:HumansCells
    253. Imamura CK, Ueno NT. Health services: How can we address cancer care after a natural disaster? Nat Rev Clin Oncol. 2011 Jun 07; 8(7):387-8. PMID: 21647194.
      Citations: 5     Fields:    Translation:Humans
    254. Niikura N, Liu J, Costelloe CM, Palla SL, Madewell JE, Hayashi N, Yu TK, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT. Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer. Oncologist. 2011; 16(6):772-82. PMID: 21632453.
      Citations: 5     Fields:    Translation:Humans
    255. Ueno NT, Zhang D. Targeting EGFR in Triple Negative Breast Cancer. J Cancer. 2011; 2:324-8. PMID: 21716849.
      Citations: 60     
    256. Hayashi N, Nakamura S, Tokuda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Serum HER2 levels determined by two methods in patients with metastatic breast cancer. Int J Clin Oncol. 2012 Feb; 17(1):55-62. PMID: 21607830.
      Citations: 2     Fields:    Translation:Humans
    257. Bregni M, Childs RW, Ueno NT. 4th Edition of the International Autologous and Allogeneic Cell Therapy for Solid Tumors (ATST) Meeting. J Cancer. 2011; 2:307-8. PMID: 21716846.
      Citations:    
    258. Cheng YC, Ueno NT. Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer. 2012 Jul; 19(3):191-9. PMID: 21567170.
      Citations: 32     Fields:    Translation:Humans
    259. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 May 11; 305(18):1873-81. PMID: 21558518.
      Citations: 305     Fields:    Translation:Humans
    260. Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, Ueno NT, Theriault RL. Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. Oncologist. 2011; 16(2):155-64. PMID: 21266401.
      Citations: 34     Fields:    Translation:Humans
    261. Hayashi N, Nakamura S, Yagata H, Shimoda Y, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. Int J Clin Oncol. 2011 Oct; 16(5):596-600. PMID: 21210173.
      Citations: 3     Fields:    Translation:HumansCells
    262. Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat. 2011 Feb; 125(3):785-95. PMID: 21153052.
      Citations: 32     Fields:    Translation:HumansCells
    263. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. 2011 May 01; 117(9):1819-26. PMID: 21509759.
      Citations: 56     Fields:    Translation:HumansPHPublic Health
    264. Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer. 2011 Jul 15; 129(2):417-23. PMID: 20857493.
      Citations: 56     Fields:    Translation:HumansCells
    265. Zhang D, Tari AM, Akar U, Arun BK, LaFortune TA, Nieves-Alicea R, Hortobagyi GN, Ueno NT. Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹° p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer. Mol Cancer Ther. 2010 Nov; 9(11):3090-9. PMID: 21045138.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    266. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, Lucci A, Ueno NT, Ueno N, Cristofanilli M. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010 Nov-Dec; 60(6):351-75. PMID: 20959401.
      Citations: 125     Fields:    Translation:Humans
    267. Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. Br J Cancer. 2010 Oct 26; 103(9):1331-4. PMID: 20877352.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    268. Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, Ueno NT. Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol. 2010 Nov; 7(11):641-51. PMID: 20808302.
      Citations: 44     Fields:    Translation:HumansCells
    269. De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med. 2010 Aug; 51(8):1213-8. PMID: 20660382.
      Citations: 22     Fields:    Translation:HumansCells
    270. Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen E, Li L, Rodriguez AA, Landis MD, Lucci A, Ueno NT, Robertson F, Xu W, Lacerda L, Buchholz TA, Cristofanilli M, Reuben JM, Lewis MT, Woodward WA. Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Mol Cancer. 2010 Jul 08; 9:180. PMID: 20615238.
      Citations: 38     Fields:    Translation:HumansCells
    271. Ueno NT, Ito TD, Grigsby RK, Black MV, Apted J. ABC conceptual model of effective multidisciplinary cancer care. Nat Rev Clin Oncol. 2010 Sep; 7(9):544-7. PMID: 20603648.
      Citations: 7     Fields:    Translation:Humans
    272. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011 Mar; 22(3):515-523. PMID: 20603440.
      Citations: 163     Fields:    Translation:Humans
    273. Cheng YC, Ueno NT. Is high-dose chemotherapy with autologous hematopoietic stem cell transplantation in breast cancer patients a done deal? Womens Health (Lond). 2010 Jul; 6(4):481-5. PMID: 20597609.
      Citations: 1     Fields:    Translation:Humans
    274. Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010 Jun 28; 1:80-92. PMID: 20842228.
      Citations: 79     
    275. Niikura N, Ueno NT. The Role of F-FDG-Positron Emission Tomography/Computed Tomography in Staging Primary Breast Cancer. J Cancer. 2010 Jun 22; 1:51-3. PMID: 20842224.
      Citations: 3     
    276. Yamauchi H, Ueno NT. Targeted therapy in inflammatory breast cancer. Cancer. 2010 Jun 01; 116(11 Suppl):2758-9. PMID: 20503407.
      Citations: 7     Fields:    Translation:HumansCells
    277. Watanabe Y, Yamasaki F, Kajiwara Y, Saito T, Nishimoto T, Bartholomeusz C, Ueno NT, Sugiyama K, Kurisu K. Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol. 2010 Dec; 100(3):449-57. PMID: 20455002.
      Citations: 8     Fields:    Translation:Humans
    278. Dawood S, Ueno NT, Valero V, Andreopoulou E, Hsu L, Lara J, Woodward W, Buchholz TA, Hortobagyi GN, Cristofanilli M. Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol. 2010 Dec; 21(12):2348-2355. PMID: 20439340.
      Citations: 12     Fields:    Translation:Humans
    279. Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN, Arun B. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther. 2010 May; 9(5):1180-7. PMID: 20423989.
      Citations: 20     Fields:    Translation:HumansAnimals
    280. Reuben JM, Lee BN, Li C, Gao H, Broglio KR, Valero V, Jackson SA, Ueno NT, Krishnamurthy S, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. Breast J. 2010 May-Jun; 16(3):327-30. PMID: 20408820.
      Citations: 9     Fields:    Translation:HumansCells
    281. Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NT. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res. 2010 Mar 15; 16(6):1802-11. PMID: 20215547.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    282. Imamura CK, Takebe N, Nakamura S, Saya H, Ueno NT. Experimental therapies: Investigator-initiated cancer trials with INDs for approval in Japan. Nat Rev Clin Oncol. 2010 Mar; 7(3):127-8. PMID: 20190792.
      Citations: 2     Fields:    Translation:Humans
    283. Debeb BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, Reuben J, Lucci A, Cristofanilli M, Woodward WA. Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):889-95. PMID: 20159363.
      Citations: 22     Fields:    Translation:HumansCells
    284. Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, Theriault RL, Hortobagyi GN, Ueno NT. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 2010 Feb 16; 102(4):651-7. PMID: 20104228.
      Citations: 29     Fields:    Translation:Humans
    285. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM, Anderson ML, Matzuk MM. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol. 2010 Feb; 24(2):447-63. PMID: 20081105.
      Citations: 102     Fields:    Translation:HumansCells
    286. Cheng YC, Rondón G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Champlin RE, Ueno NT. Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Int J Hematol. 2009 Dec; 90(5):627-634. PMID: 19998065.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    287. Vinh-Hung V, Nguyen NP, Cserni G, Truong P, Woodward W, Verkooijen HM, Promish D, Ueno NT, Tai P, Nieto Y, Joseph S, Janni W, Vicini F, Royce M, Storme G, Wallace AM, Vlastos G, Bouchardy C, Hortobagyi GN. Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. Future Oncol. 2009 Dec; 5(10):1585-603. PMID: 20001797.
      Citations: 16     Fields:    Translation:Humans
    288. Nakayama K, Liu P, Detry M, Schover LR, Milbourne A, Neumann J, Rondon G, Thewes B, Champlin RE, Ueno NT. Receiving information on fertility- and menopause-related treatment effects among women who undergo hematopoietic stem cell transplantation: changes in perceived importance over time. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1465-74. PMID: 19822307.
      Citations: 14     Fields:    Translation:Humans
    289. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res. 2009 Nov 01; 15(21):6639-48. PMID: 19825949.
      Citations: 68     Fields:    Translation:HumansAnimalsCells
    290. Kai K, Nagano O, Sugihara E, Arima Y, Sampetrean O, Ishimoto T, Nakanishi M, Ueno NT, Iwase H, Saya H. Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model. Cancer Sci. 2009 Dec; 100(12):2275-82. PMID: 19737148.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    291. Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther. 2009 Aug; 8(8):2375-82. PMID: 19671744.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    292. Ueno NT, de Souza JA, Booser D, Nakayama K, Madewell J, Wendt RE, Hortobagyi GN, Podoloff D, Champlin RE. Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer. Clin Breast Cancer. 2009 Aug; 9(3):173-7. PMID: 19661041.
      Citations: 4     Fields:    Translation:Humans
    293. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol. 2010 Jan; 21(1):33-9. PMID: 19602564.
      Citations: 31     Fields:    Translation:HumansCells
    294. Mego M, De Giorgi U, Hsu L, Ueno NT, Valero V, Jackson S, Andreopoulou E, Kau SW, Reuben JM, Cristofanilli M. Circulating tumor cells in metastatic inflammatory breast cancer. Ann Oncol. 2009 Nov; 20(11):1824-8. PMID: 19556320.
      Citations: 11     Fields:    Translation:HumansCells
    295. Costelloe CM, Rohren EM, Madewell JE, Hamaoka T, Theriault RL, Yu TK, Lewis VO, Ma J, Stafford RJ, Tari AM, Hortobagyi GN, Ueno NT. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol. 2009 Jun; 10(6):606-14. PMID: 19482249.
      Citations: 48     Fields:    Translation:Humans
    296. Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT. Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol. 2009 Jul; 6(7):387-94. PMID: 19468291.
      Citations: 24     Fields:    Translation:HumansCells
    297. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009 Jul 10; 27(20):3303-11. PMID: 19451443.
      Citations: 46     Fields:    Translation:HumansCells
    298. de Souza JA, Davis ML, Rondon G, Cheng YC, Jones RB, Champlin RE, Ueno NT. Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. Bone Marrow Transplant. 2009 Jul; 44(2):81-7. PMID: 19448681.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    299. Nakayama S, Torikoshi Y, Takahashi T, Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K, Hortobagyi GN, Noguchi S, Sakai T, Ishihara H, Ueno NT. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res. 2009; 11(1):R12. PMID: 19239702.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    300. Bartholomeusz C, Rosen D, Wei C, Kazansky A, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J, Ueno NT. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res. 2008 Nov 15; 68(22):9302-10. PMID: 19010903.
      Citations: 34     Fields:    Translation:HumansCells
    301. Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther. 2008 Jul; 7(7):1846-50. PMID: 18644997.
      Citations: 37     Fields:    Translation:HumansCells
    302. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Jun 15; 111(12):5530-6. PMID: 18411419.
      Citations: 112     Fields:    Translation:HumansCellsCTClinical Trials
    303. Dawood S, Ueno NT, Cristofanilli M. The medical treatment of inflammatory breast cancer. Semin Oncol. 2008 Feb; 35(1):64-71. PMID: 18308147.
      Citations: 9     Fields:    Translation:Humans
    304. Nakayama K, Milbourne A, Schover LR, Champlin RE, Ueno NT. Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. Nat Clin Pract Oncol. 2008 Feb; 5(2):78-89. PMID: 18235440.
      Citations: 6     Fields:    Translation:Humans
    305. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008 Feb; 93(2):257-64. PMID: 18223284.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    306. Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwieser D. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant. 2008 Mar; 41(6):537-45. PMID: 18084340.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    307. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007 Oct 01; 110(7):1436-44. PMID: 17694554.
      Citations: 69     Fields:    Translation:Humans
    308. Hayes JM, Kim SK, Abitua PB, Park TJ, Herrington ER, Kitayama A, Grow MW, Ueno N, Wallingford JB. Identification of novel ciliogenesis factors using a new in vivo model for mucociliary epithelial development. Dev Biol. 2007 Dec 01; 312(1):115-30. PMID: 17961536.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    309. Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, Ueno NT. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther. 2007 Aug; 6(8):2168-77. PMID: 17671085.
      Citations: 29     Fields:    Translation:HumansCells
    310. Nakayama K, Tannir NM, Liu P, Wathen JK, Cheng YC, Champlin RE, Ueno NT. Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007 Aug; 13(8):975-85. PMID: 17640602.
      Citations: 2     Fields:    Translation:Humans
    311. Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res. 2007 Jun 15; 67(12):5779-88. PMID: 17575145.
      Citations: 47     Fields:    Translation:HumansCells
    312. Uno T, Mitsuhashi A, Isobe K, Yamamoto S, Kawakami H, Ueno N, Usui H, Tate S, Kawata T, Ito H. Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix. Int J Gynecol Cancer. 2008 Jan-Feb; 18(1):80-4. PMID: 17466053.
      Citations: 8     Fields:    Translation:Humans
    313. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer. 2007 Feb; 7(6):471-9. PMID: 17386124.
      Citations: 61     Fields:    Translation:HumansCells
    314. Itamochi H, Kigawa J, Kanamori Y, Oishi T, Bartholomeusz C, Nahta R, Esteva FJ, Sneige N, Terakawa N, Ueno NT. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Mol Cancer Ther. 2007 Jan; 6(1):227-35. PMID: 17218636.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    315. Sugimoto T, Bartholomeusz C, Tari AM, Ueno NT. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. Breast Cancer Res. 2007; 9(4):R41. PMID: 17612393.
      Citations: 3     Fields:    Translation:HumansCells
    316. Ueno NT, Childs RW. What's past is prologue: lessons learned and the need for further development of allogeneic hematopoietic stem cell transplantation for renal cell carcinoma. Biol Blood Marrow Transplant. 2007 Jan; 13(1):31-3. PMID: 17222750.
      Citations: 5     Fields:    Translation:Humans
    317. Ueno NT, Cheng YC. The future of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma in the era of target-specific therapy. Bone Marrow Transplant. 2006 Dec; 38(11):711-4. PMID: 17106451.
      Citations:    Fields:    Translation:Humans
    318. Nakayama K, Ueno NT. American Society of Clinical Oncology recommendations on fertility preservation should be implemented regardless of disease status or previous treatments. J Clin Oncol. 2006 Nov 20; 24(33):5334-5; author reply 5337-8. PMID: 17114671.
      Citations: 1     Fields:    Translation:Humans
    319. Bregni M, Ueno NT, Childs R. The second international meeting on allogeneic transplantation in solid tumors. Bone Marrow Transplant. 2006 Oct; 38(8):527-37. PMID: 16953213.
      Citations: 7     Fields:    Translation:HumansAnimals
    320. Qazilbash MH, Ueno NT, Hosing C, De Lima M, Cortes J, Massaro A, Rivera Z, Deavers M, Adachi JA, Champlin RE. Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2006 Sep; 38(5):393-4. PMID: 16845427.
      Citations: 5     Fields:    Translation:Humans
    321. Woodward WA, Vinh-Hung V, Ueno NT, Cheng YC, Royce M, Tai P, Vlastos G, Wallace AM, Hortobagyi GN, Nieto Y. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol. 2006 Jun 20; 24(18):2910-6. PMID: 16782931.
      Citations: 63     Fields:    Translation:Humans
    322. Nahta R, Yuan LX, Fiterman DJ, Zhang L, Symmans WF, Ueno NT, Esteva FJ. B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells. Mol Cancer Ther. 2006 Jun; 5(6):1593-601. PMID: 16818519.
      Citations: 20     Fields:    Translation:HumansCells
    323. Itamochi H, Yamasaki F, Sudo T, Takahashi T, Bartholomeusz C, Das S, Terakawa N, Ueno NT. Reduction of radiation-induced apoptosis by specific expression of Bcl-2 in normal cells. Cancer Gene Ther. 2006 May; 13(5):451-9. PMID: 16294215.
      Citations: 1     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    324. Ueno NT, Konoplev S, Buchholz TA, Smith T, Rondón G, Anderlini P, Giralt SA, Gajewski JL, Donato ML, Cristofanilli M, Champlin RE. High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. Bone Marrow Transplant. 2006 May; 37(10):929-35. PMID: 16565737.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    325. Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NT. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene. 2006 Jan 05; 25(1):79-90. PMID: 16170361.
      Citations: 20     Fields:    Translation:HumansCells
    326. Cheng YC, Saliba RM, Rondón G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica. 2005 Dec; 90(12):1725-6. PMID: 16330461.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    327. Bartholomeusz C, Itamochi H, Yuan LX, Esteva FJ, Wood CG, Terakawa N, Hung MC, Ueno NT. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res. 2005 Sep 15; 65(18):8406-13. PMID: 16166319.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    328. Takahashi T, Yamasaki F, Sudo T, Itamochi H, Adachi S, Tamamori-Adachi M, Ueno NT. Cyclin A-associated kinase activity is needed for paclitaxel sensitivity. Mol Cancer Ther. 2005 Jul; 4(7):1039-46. PMID: 16020661.
      Citations: 11     Fields:    Translation:HumansCells
    329. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005 May; 35(10):943-51. PMID: 15806128.
      Citations: 30     Fields:    Translation:Humans
    330. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005 Feb; 11(2):108-14. PMID: 15682071.
      Citations: 35     Fields:    Translation:Humans
    331. Khorshid O, Hosing C, Bibawi S, Ueno N, Reveille J, Mayes MD, Champlin RE. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. J Rheumatol. 2004 Dec; 31(12):2513-6. PMID: 15570660.
      Citations: 11     Fields:    Translation:Humans
    332. Cheng YC, Rondón G, Yang Y, Smith TL, Gajewski JL, Donato ML, Shpall EJ, Jones R, Hortobagyi GN, Champlin RE, Ueno NT. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant. 2004 Nov; 10(11):794-804. PMID: 15505610.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    333. Anderlini P, Acholonu SA, Okoroji GJ, Andersson BS, Couriel DR, De Lima MJ, Donato ML, Khouri IF, Giralt SA, Ueno NT, Champlin RE. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant. 2004 Sep; 34(6):511-4. PMID: 15273710.
      Citations: 10     Fields:    Translation:Humans
    334. Ueno NT, Shpall EJ, Champlin RE, Jones RB. Graft--versus--breast cancer effect by allogeneic hematopoietic stem-cell transplantation: a possible new frontier. J Clin Oncol. 2004 Oct 01; 22(19):3846-7. PMID: 15314060.
      Citations:    Fields:    
    335. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004 Jul 15; 22(14):2942-53. PMID: 15254062.
      Citations: 174     Fields:    Translation:Humans
    336. Hu Q, Ueno N, Behringer RR. Restriction of BMP4 activity domains in the developing neural tube of the mouse embryo. EMBO Rep. 2004 Jul; 5(7):734-9. PMID: 15218525.
      Citations: 12     Fields:    Translation:AnimalsCells
    337. Escalón MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, Donato M, McLaughlin P, Khouri IF. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol. 2004 Jun 15; 22(12):2419-23. PMID: 15197204.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    338. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004 Jun 01; 64(11):3981-6. PMID: 15173011.
      Citations: 108     Fields:    Translation:HumansCells
    339. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004 Aug 01; 104(3):865-72. PMID: 15090449.
      Citations: 94     Fields:    Translation:Humans
    340. Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res. 2004 Apr 01; 64(7):2502-8. PMID: 15059905.
      Citations: 90     Fields:    Translation:HumansCells
    341. Sudo T, Ueno NT, Saya H. Functional analysis of APC-Cdh1. Methods Mol Biol. 2004; 281:189-98. PMID: 15220530.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    342. Cheng YC, Ueno NT. [Allogeneic hematopoietic stem cell transplantation for solid tumors in the United States: a review]. Nihon Rinsho. 2003 Sep; 61(9):1619-34. PMID: 14515734.
      Citations:    Fields:    Translation:Humans
    343. Trent JC, Charnsangavej C, Shah H, Giralt S, Ueno NT. Hepatic haematoma after allogeneic transplantation. Br J Haematol. 2003 Sep; 122(5):694. PMID: 12930380.
      Citations:    Fields:    Translation:Humans
    344. Ueno NT, Cheng YC, Rondón G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003 Nov 15; 102(10):3829-36. PMID: 12881308.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    345. Wong R, Rondon G, Saliba RM, Shannon VR, Giralt SA, Champlin RE, Ueno NT. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. Bone Marrow Transplant. 2003 Jun; 31(12):1157-63. PMID: 12796796.
      Citations: 7     Fields:    Translation:Humans
    346. Montemurro F, Rondón G, Munsell M, Smith TL, Donato ML, Gajewski JL, Rahman ZU, Buzdar AU, Champlin RE, Ueno NT. Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. Biol Blood Marrow Transplant. 2003 May; 9(5):330-40. PMID: 12766883.
      Citations: 2     Fields:    Translation:Humans
    347. Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J, Molldrem J, Ueno N, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Williston Park). 2003 Jan; 17(1):94-100; discussion 103-7. PMID: 12599934.
      Citations: 7     Fields:    Translation:Humans
    348. Ueno NT, Bartholomeusz C, Xia W, Anklesaria P, Bruckheimer EM, Mebel E, Paul R, Li S, Yo GH, Huang L, Hung MC. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res. 2002 Nov 15; 62(22):6712-6. PMID: 12438271.
      Citations: 16     Fields:    Translation:Humans
    349. Ueno NT, Anagnostopoulos A, Rondón G, Champlin RE, Mikhailova N, Pankratova OS, Zoubarovskaya LS, Semenova EV, Afanasyev BV, O'Brien S, Andreeff M, Zaritskey AY. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol. 2002 Oct; 119(1):131-4. PMID: 12358917.
      Citations: 6     Fields:    Translation:Humans
    350. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Ueno NT, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin R. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002 Sep; 30(6):367-73. PMID: 12235521.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    351. Montemurro F, Rondón G, Ueno NT, Munsell M, Gajewski JL, Champlin RE. Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy. Bone Marrow Transplant. 2002 May; 29(10):861-6. PMID: 12058236.
      Citations: 2     Fields:    Translation:Humans
    352. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Körbling M, Martin T, Ueno NT, Champlin RE, Khouri IF. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol. 2002 Mar; 13(3):450-9. PMID: 11996478.
      Citations: 14     Fields:    Translation:Humans
    353. Gajewski JL, Rondon G, Donato ML, Anderlini P, Korbling M, Ippoliti C, Benyunes M, Miller LL, LaTemple D, Jones D, Ashby M, Hellmann S, Durett A, Lauppe J, Geisler D, Khouri IF, Giralt SA, Andersson B, Ueno NT, Champlin R. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. Biol Blood Marrow Transplant. 2002; 8(10):550-6. PMID: 12434950.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    354. Kim YS, Konoplev SN, Montemurro F, Hoy E, Smith TL, Rondón G, Champlin RE, Sahin AA, Ueno NT. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res. 2001 Dec; 7(12):4008-12. PMID: 11751494.
      Citations: 7     Fields:    Translation:Humans
    355. Meisler A. E1A is an oncogene and may immortalize normal cells, especially in combination with other oncoproteins. J Clin Oncol. 2001 Nov 01; 19(21):4183-4. PMID: 11689591.
      Citations:    Fields:    Translation:Humans
    356. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Oct 01; 92(7):1775-82. PMID: 11745249.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    357. Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J. 2001 Sep-Oct; 7(5):413-20. PMID: 11693900.
      Citations: 15     Fields:    Translation:Humans
    358. Ghosh S, Champlin RE, Ueno NT, Anderlini P, Rolston K, Raad I, Kontoyiannis D, Jacobson K, Luna M, Tarrand J, Whimbey E. Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant. 2001 Aug; 28(3):271-5. PMID: 11535995.
      Citations: 12     Fields:    Translation:Humans
    359. Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol. 2001 Aug; 67(4):227-33. PMID: 11443634.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    360. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 2001 Jul 15; 19(14):3422-33. PMID: 11454891.
      Citations: 31     Fields:    Translation:HumansCellsCTClinical Trials
    361. Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt S. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001 Jun; 27(12):1221-5. PMID: 11548839.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    362. Champlin R, Khouri I, Anderlini P, Gajewski J, Kornblau S, Molldrem J, Shimoni A, Ueno N, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2001 May; 27 Suppl 2:S13-22. PMID: 11436116.
      Citations: 6     Fields:    Translation:Humans
    363. Konoplev S, Champlin RE, Giralt S, Ueno NT, Khouri I, Raad I, Rolston K, Jacobson K, Tarrand J, Luna M, Nguyen Q, Whimbey E. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant. 2001 Apr; 27(8):877-81. PMID: 11477447.
      Citations: 21     Fields:    Translation:Humans
    364. Shimoni A, Smith TL, Aleman A, Weber D, Dimopoulos M, Anderlini P, Andersson B, Claxton D, Ueno NT, Khouri I, Donato M, Korbling M, Alexanian R, Champlin R, Giralt S. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant. 2001 Apr; 27(8):821-8. PMID: 11477439.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    365. Shaikh ZH, Ueno NT, Kontoyiannis DP. Fatal Salmonella group G enteritis mimicking intestinal graft-versus-host disease in a bone marrow transplant recipient. Transpl Infect Dis. 2001 Mar; 3(1):29-33. PMID: 11429037.
      Citations: 1     Fields:    Translation:HumansCells
    366. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Feb 01; 97(3):631-7. PMID: 11157478.
      Citations: 100     Fields:    Translation:HumansCTClinical Trials
    367. Ueno NT, Yu D, Hung MC. E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. Breast Cancer. 2001; 8(4):285-93. PMID: 11791119.
      Citations: 9     Fields:    Translation:HumansAnimals
    368. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, Ueno N, Giralt S, Anderlini P. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000 Oct; 111(1):18-29. PMID: 11091179.
      Citations: 31     Fields:    Translation:HumansCells
    369. Montemurro F, Ueno NT, Rondón G, Aglietta M, Champlin RE. High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. Clin Breast Cancer. 2000 Oct; 1(3):197-209; discussion 210. PMID: 11899644.
      Citations: 2     Fields:    Translation:Humans
    370. Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Körbling MJ, Manning J, Romaguera J, Sarris A, Hagemeister F, Mclaughlin P, Cabanillas F, Champlin RE. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant. 2000 Sep; 26(6):615-20. PMID: 11041566.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    371. Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin RE. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant. 2000 Jun; 25(11):1137-40. PMID: 10849525.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    372. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000 Jan; 6(1):250-9. PMID: 10656456.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    373. Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H, Khouri IF, Folloder J, Ueno NT, Mehra R, Ippoliti C, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Anderlini P, Andersson BS, Champlin R. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant. 2000; 6(2A):190-7. PMID: 10816027.
      Citations: 1     Fields:    Translation:Humans
    374. Hung MC, Hortobagyi GN, Ueno NT. Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. Adv Exp Med Biol. 2000; 465:171-80. PMID: 10810625.
      Citations: 16     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    375. Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Körbling M, Giralt S, Gajewski J, Fischer H, Donato M, Cleary K, Claxton D, Chan KW, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999 Oct; 24(7):763-8. PMID: 10516680.
      Citations: 18     Fields:    Translation:Humans
    376. Champlin R, Khouri I, Kornblau S, Marini F, Anderlini P, Ueno NT, Molldrem J, Giralt S. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol Oncol Clin North Am. 1999 Oct; 13(5):1041-57, vii-viii. PMID: 10553260.
      Citations: 9     Fields:    Translation:Humans
    377. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, Körbling M, Huh YO, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999 Aug 15; 94(4):1465-70. PMID: 10438735.
      Citations: 42     Fields:    Translation:Humans
    378. Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Körbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32. PMID: 10416001.
      Citations: 13     Fields:    Translation:Humans
    379. Ueno NT, Xia W, Tucker SD, Zhang S, Lopez-Berestein G, Huang L, Hung MC. Issues in the development of gene therapy: preclinical experiments in E1A gene delivery. Oncol Rep. 1999 Mar-Apr; 6(2):257-62. PMID: 10022986.
      Citations:    Fields:    Translation:HumansCells
    380. Ueno NT, Hortobagyi GN, Champlin RE. Allogeneic peripheral blood progenitor cell transplantation in solid tumors. Cancer Treat Res. 1999; 101:133-56. PMID: 10800648.
      Citations:    Fields:    Translation:Humans
    381. Ueno NT, Amato RJ, Ro JJ, Weber RS. Primary malignant teratoma of the thyroid gland: report and discussion of two cases. Head Neck. 1998 Oct; 20(7):649-53. PMID: 9744468.
      Citations: 4     Fields:    Translation:Humans
    382. Khouri IF, Keating M, Körbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998 Aug; 16(8):2817-24. PMID: 9704734.
      Citations: 109     Fields:    Translation:Humans
    383. Ueno NT, Rondón G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Körbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998 Mar; 16(3):986-93. PMID: 9508181.
      Citations: 22     Fields:    Translation:Humans
    384. Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene. 1997 Aug 18; 15(8):953-60. PMID: 9285690.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    385. Ueno NT, Zhao S, Robertson LE, Consoli U, Andreeff M. 2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome. Leukemia. 1997 Aug; 11(8):1386-90. PMID: 9264399.
      Citations: 1     Fields:    Translation:Humans
    386. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, Frye D, Hortobagyi GN. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997; 40(4):321-9. PMID: 9225950.
      Citations: 59     Fields:    Translation:Humans
    387. Maeno M, Mead PE, Kelley C, Xu RH, Kung HF, Suzuki A, Ueno N, Zon LI. The role of BMP-4 and GATA-2 in the induction and differentiation of hematopoietic mesoderm in Xenopus laevis. Blood. 1996 Sep 15; 88(6):1965-72. PMID: 8822915.
      Citations: 43     Fields:    Translation:AnimalsCells
    388. Ueno N, Kiyokawa N, Hung M. Growth suppression of low HER-2/neu-expressing breast cancer cell line MDA-MB-435 by tyrosine kinase inhibitor emodin. Oncol Rep. 1996 May; 3(3):509-11. PMID: 21594402.
      Citations: 3     Fields:    
    389. Mishina Y, Suzuki A, Ueno N, Behringer RR. Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Genes Dev. 1995 Dec 15; 9(24):3027-37. PMID: 8543149.
      Citations: 240     Fields:    Translation:AnimalsCells
    390. Ueno NT, Zukiwski AA. Combination recombinant interleukin-2, recombinant interferon-alpha, and 5-fluorouracil for treatment of metastatic renal cell carcinoma. Am J Clin Oncol. 1995 Aug; 18(4):358-62. PMID: 7625380.
      Citations:    Fields:    Translation:Humans
    391. Mishina Y, Suzuki A, Gilbert DJ, Copeland NG, Jenkins NA, Ueno N, Behringer RR. Genomic organization and chromosomal location of the mouse type I BMP-2/4 receptor. Biochem Biophys Res Commun. 1995 Jan 05; 206(1):310-7. PMID: 7818535.
      Citations: 7     Fields:    Translation:AnimalsCells
    392. Yabushita H, Sawaguchi K, Ueno N, Hieda S, Noguchi M, Ishihara M. [Experimental study on the effect of UFT with concomitant radiotherapy of uterine cervical cancer]. Gan To Kagaku Ryoho. 1989 Feb; 16(2):235-41. PMID: 2493223.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    393. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes and Control. 27:359-366.
    394. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer.
    395. In reply [8]. Journal of Clinical Oncology. 23:4803.
    396. Allogeneic hematopoietic transplantation for indolent lymphomas. Blood. 96.
    397. Gene expression profiling of inflammatory breast cancer. Breast Diseases. 22:30-32.
    398. Erratum. Breast Cancer Research and Treatment. 152:417.
    399. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. Breast Diseases. 26:251-252.
    400. Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. Journal of Cancer. 6:1306-1319.
    401. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Modern Pathology.
    402. Gemcitabine overcomes erlotinib resistance in EGFR overexpressing cancer cells through downregulation of Akt. Journal of Cancer. 2:435-442.
    403. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Annals of Oncology. 21:33-39.
    404. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun. Oncogene.
    405. Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. Oncotarget. 7:82482-82492.
    406. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Oncology. 17:94-100.
    407. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 1-8.
    408. High her2/centromeric probeforchromosome17fluorescence insitu hybridization ratio predicts pathologic complete response and survival outcomein patients receiving neoadjuvant systemic therapy with trastuzumab for her2-overexpressing locally advanced breast cancer. Oncologist. 21:21-27.
    409. 4th edition of the International Autologous and Allogeneic Cell Therapy for Solid Tumors (ATST) meeting. Journal of Cancer. 2:307-308.
    410. Inflammatory breast cancer. PLoS One. 11.
    411. Antitumor activity of KW-2450 against triple-negative breast cancer by inhibiting Aurora A and B kinases. Molecular Cancer Therapeutics. 14:2687-2699.
    412. Inflammation mediated metastasis. PLoS One. 10.
    413. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 7:76362-76373.
    414. P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells (Cancer Research (June 1, 2004) 64 (3981-3986)). Cancer Research. 68:10005.
    415. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. Journal of Clinical Oncology. 33:2753-2762.
    416. Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient. Journal of Cancer. 4:697-702.
    417. Reply to P.J. van Diest et al. Journal of Clinical Oncology. 30:3032-3033.
    418. Angiogenesis and lymphangiogenesis in IBC. 225-242.
    419. Inflammatory breast cancer registry. 21-26.
    420. Reply. British Journal of Cancer. 103:927.
    421. Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget. 7:28329-28339.
    422. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 534:47-54.
    423. Location of receipt of initial treatment and outcomes in long-term breast cancer survivors. PLoS One. 12.
    424. Signaling pathways in inflammatory breast cancer. 151-160.
    425. The role of 18F-FDG-positron emission tomography/computed tomography in staging primary breast cancer. Journal of Cancer. 1:51-53.
    426. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget. 7:18531-18540.
    427. miR-141-mediated regulation of brain metastasis from breast cancer. Journal of the National Cancer Institute. 108.
    428. The role of inflammation in inflammatory breast cancer. 53-73.
    429. Association of body mass index changes during neoadjuvant chemotherapy with pathologic complete response and clinical outcomes in patients with locally advanced breast cancer. Journal of Cancer. 6:310-318.
    430. Breast cancer biomarkers. Current Breast Cancer Reports. 5:284-292.
    431. Allogeneic transplantation in metastatic breast cancer. Seminars in Breast Disease. 3:176-184.
    432. Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience. 2:576-580.
    433. The association between EGFR and cMET expression and phosphorylation and its prognostic implication in patients with breast cancer. PLoS One. 11.
    434. Inflammatory breast cancer.
    435. MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in Breast Cancer. International Journal of Radiation Oncology Biology Physics.
    436. Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. Breast Cancer Research. 17.
    437. Has racial difference in cause-specific death improved in older patients with late-stage breast cancer?. Annals of Oncology. 26:2161-2168.
    438. Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. SpringerPlus. 3:1-9.
    439. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in inflammatory breast cancer. 127-138.
    440. cMET activation and EGFR-directed therapy resistance in triple-negative breast cancer. Journal of Cancer. 5:745-753.
    441. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Research and Treatment. 154:495-508.
    442. Effect of 21-gene RT-PCR assay on adjuvant therapy and outcomes in patients with stage i breast cancer. Clinical Breast Cancer. 15:458-466.
    443. Effects of CDK4/6 inhibition in hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer cells with acquired resistance to paclitaxel. Journal of Cancer. 7:947-956.
    444. Cancer response criteria and bone metastases. Journal of Cancer. 1:80-92.
    445. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. Molecular Oncology. 9:1155-1168.
    446. Neoadjuvant nab-paclitaxel in the treatment of breast cancer. Breast Cancer Research and Treatment. 156:427-440.
    447. A pilot study of trastuzumab plus GM-CSF for patients with trastuzumab-resistant, HER2-overexpressing metastatic breast cancer. Clinical Advances in Hematology and Oncology. 4:25-29.
    448. Growth suppression of low HER-2/neu-expressing breast cancer cell line MDA-MB-435 by tyrosine kinase inhibitor emodin. Oncology Reports. 3:509-511.
    449. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Research. 17.
    450. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget. 6:12890-12908.
    451. Risk factors for inflammatory breast cancer and other invasive breast cancers. Breast Diseases. 25:124-125.
    452. Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer. Breast Diseases. 21:375-376.
    453. Allogeneic transplantation with nonmyeloablative or reduced intensity conditioning. Blood. 96.
    454. Bone metastases. 591-609.
    455. Fuel, electricity, ER and HER2-a hybrid-car model of breast cancer. Nature Reviews Clinical Oncology.
    456. Therapeutic decision making in stem cell transplantation for breast cancer. 165-168.
    457. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. British Journal of Cancer.
    458. Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer. Journal of Cancer. 7:1095-1104.
    459. Erratum. CA Cancer Journal for Clinicians. 61:134.
    460. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thrombosis and Haemostasis. 113:593-598.
    461. Impact of clinical trial on survival outcomes. Breast Cancer Research and Treatment. 1-9.
    462. The role of inflammation in inflammatory breast cancer. 53-73.
    463. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Research and Treatment.
    464. Bone metastasis of breast cancer. 189-209.
    465. Targeting EGFR in triple negative breast cancer. Journal of Cancer. 2:324-328.
    466. Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proceedings of the National Academy of Sciences of the United States of America. 113:12780-12785.
    467. Introduction. 1-2.
    468. Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. Breast Cancer Research and Treatment. 160:101-109.
    469. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. British Journal of Cancer. 113:1003-1009.
    470. MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model. Molecular Cancer Therapeutics. 14:2773-2781.
    471. NSAID use reduces breast cancer recurrence in overweight and obese women. Breast Diseases. 26:88-90.
    472. Systemic and targeted therapy. 85-99.
    473. Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer. International Journal of Radiation Oncology Biology Physics.
    474. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. Breast Diseases. 15:73-76.
    475. Autologous hematopoietic stem cell transplantation in breast cancer. Breast Diseases. 15:113-117.
    UENO's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (950)
    Explore
    _
    Co-Authors (223)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _